SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

P5 - Poster Session V

Event Time: Thursday April 27, 2017 8:30 am to 7:00 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Epilepsy/Clinical Neurophysiology (EEG), Movement Disorders, MS and CNS Inflammatory Disease, Neuro Trauma, Critical Care, and Sports Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-oncology, Neuro-ophthalmology/Neuro-otology, Neuro-rehabilitation
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 pm to 7:00 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
11:45 AM - 11:50 AM P5.101 None  
11:50 AM - 11:55 AM P5.102 None  
11:55 AM - 12:00 PM P5.103 None  
12:00 PM - 12:05 PM P5.104 None  
12:05 PM - 12:10 PM P5.105 None  
12:10 PM - 12:15 PM P5.106 None  
12:15 PM - 12:20 PM P5.107 None  
12:20 PM - 12:25 PM P5.108 None  
12:25 PM - 12:30 PM P5.109 None  
12:30 PM - 12:35 PM P5.110 None  
5:30 PM - 7:00 PM Poster Author Standby Time None  

Disclosures

Speaker Disclosure

Abstract Presenters

Parkinson's Disease: Non-Motor Manifestations
Start Time Pub. Title Presenter
5:30 PM 001 Comprehensive Identification of Delusions and Olfactory, Tactile, Gustatory, and Minor Hallucinations in Parkinson’s Disease Psychosis Catherine V. Kulick
Disclosure:
Dr. Kulick has nothing to disclose.

5:30 PM 002 Gender differences in motor and non-motor features in Parkinson’s Disease Therese Dunne
Disclosure:
Dr. Dunne has nothing to disclose.

5:30 PM 003 Fatigue in Parkinson’s Disease Bhavana Patel
Disclosure:
Dr. Patel has nothing to disclose.

5:30 PM 004 Leg Discomfort and Insomnia in Parkinson’s Disease Aliya Sarwar, MD
Disclosure:
Dr. Sarwar has nothing to disclose.

5:30 PM 005 Impulse Control Disorders in Parkinson’s Disease: Prevalence and Clinical Features in the Rush University Movement Disorders Clinic Michael Rossi
Disclosure:
Dr. Rossi has nothing to disclose.

5:30 PM 006 Depression in newly diagnosed Parkinson’s disease patients : a study of voxel based morphometry Seong-il Oh
Disclosure:
Dr. Oh has nothing to disclose.

5:30 PM 007 Development of dementia in a population based incidence cohort of Parkinson’s disease in Olmsted County, MN: 1991-2005 Farwa Ali, MD
Disclosure:
Dr. Ali has nothing to disclose.

5:30 PM 008 Access to Emergency Care and Outpatient Clinic Resources in Parkinson Disease with Orthostatic Hypotension. Are we missing something? Zoe Berndt
Disclosure:
Dr. Berndt has nothing to disclose.

5:30 PM 009 Causes and outcomes of hospitalization in dementia with Lewy bodies. Amir Besharat, DO
Disclosure:
Dr. Besharat has nothing to disclose.

5:30 PM 010 Demoralization in Parkinson Disease Brian Koo, MD
Disclosure:
Dr. Koo has nothing to disclose.

Movement Disorders: Deep & Non-Invasive Brain Stimulation
Start Time Pub. Title Presenter
5:30 PM 011 Deep Brain Stimulation in Early Stage Parkinson’s Disease: Long-Term Quality of Life Outcome Lauren Heusinkveld
Disclosure:
Dr. Heusinkveld has nothing to disclose.

5:30 PM 012 Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis Mallory Hacker, PhD
Disclosure:
Dr. Hacker has nothing to disclose.

5:30 PM 013 Accuracy of Placement of Deep Brain Stimulation Leads May be Better with a Staged Approach Wissam Deeb, MD
Disclosure:
Dr. Deeb has nothing to disclose.

5:30 PM 014 Meta-analysis of mortality following Subthalamic and Pallidal deep brain stimulation for patients with Parkinson's disease Ahmed Abdou Negida
Disclosure:
Dr. Abdou Negida has nothing to disclose.

5:30 PM 015 Measurement of effect of variable deep brain stimulation frequencies on static postural control in Parkinson Disease (PD) patients with Bilateral STN or GPi stimulators by employing force plate. Aman Deep, MD
Disclosure:
Dr. Deep has nothing to disclose.

5:30 PM 016 INTREPID Trial: A Prospective, Double blinded, Multi-center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple-Source, Constant-Current Rechargeable System in Parkinson’s Disease Jerrold Vitek, MD, PhD
Disclosure:
Dr. Vitek received personal compensation for activities with Abbott, Boston Scientific, Medtronic, NeuroNexus, and Great Lakes NeuroTechnologies Inc as a consultant and/or speaker.. Dr. Vitek has received research support from Boston Scientific..

5:30 PM 017 The effect of low frequency stimulation, with and without maintenance of the total electric energy delivered, on freezing of gait and other motor symptoms in PD patients who have freezing of gait at high frequency STN stimulation Tao Xie, MD
Disclosure:
Dr. Xie has nothing to disclose.

5:30 PM 018 Remotely supervised transcranial Direct Current Stimulation in Parkinson’s disease patients Shashank Agarwal, MD, MBBS
Disclosure:
Dr. Agarwal has nothing to disclose.

5:30 PM 019 DTI tractographic correlates of weight gain in Parkinson’s disease patients after STN DBS Omar Ahmad, MD
Disclosure:
Dr. Ahmad has received research support from uniQure.

Movement Disorders: Other II
Start Time Pub. Title Presenter
5:30 PM 020 Movement disorders in demyelinating diseases: a retrospective review from a tertiary academic center Gerson Suarez-Cedeno, MD
Disclosure:
Dr. Suarez-Cedeno has nothing to disclose.

5:30 PM 021 Preclinical Characterization of SAGE-217 in a Rodent Model of Oral Dyskinesia Gabriel Belfort, MD
Disclosure:
Dr. Belfort has received personal compensation for activities with Sage Therapeutics as an employee. Dr. Belfort has received research support from Sage Therapeutics.

5:30 PM 022 "Faciobrachial Dystonic Seizures. Questioning the name paradigm" Sahyli Perez Parra, MD
Disclosure:
Dr. Perez Parra has nothing to disclose.

5:30 PM 023 Neuropathology of Spastic paraplegia-15 (SPG15) mimics that of Parkinson’s Disease Hisatomo Kowa, MD, PhD
Disclosure:
Dr. Kowa has nothing to disclose.

5:30 PM 024 Stiff person syndrome masquerading as more common movement disorders David Stone, MD, PhD
Disclosure:
Dr. Stone has nothing to disclose.

5:30 PM 025 Vitamin B12 Measurements Across Neurodegenerative Disorders Nijee Luthra, MD, PhD
Disclosure:
Dr. Luthra has nothing to disclose.

5:30 PM 026 Genetic Testing for Beta-propeller Protein-Associated Neurodegeneration (BPAN) Duarte Machado, MD
Disclosure:
Dr. Machado has nothing to disclose.

5:30 PM 027 FMR1, BDNF, and COMT in Functional Movement Disorder Women Emily Tharp
Disclosure:
Dr. Tharp has nothing to disclose.

5:30 PM 028 Hereditary Spastic Paraplegias - experience of a tertiary center in Portugal Joana Ribeiro
Disclosure:
Dr. Ribeiro has nothing to disclose.

5:30 PM 029 TECPR2 mutations and HSP combined phenotype Emilia Gatto, MD
Disclosure:
scientific advisor Tuteur, speaking Bago, Novartis, Glaxo-Smith Klein, Teva, Genzyme, Boehringer Ingelheim.

5:30 PM 030 NA NA NA
Disclosure:

Neurocritical Care: Coma/Mental Status
Start Time Pub. Title Presenter
5:30 PM 031 Prediction of Sedation Score using Wireless Accelerometers Nicholas Peterson
Disclosure:
Dr. Peterson has nothing to disclose.

5:30 PM 032 Probing Consciousness in Unresponsive Wakefulness Syndrome Patients with a Vibrotactile P300-Based Brain-computer Interface Rossella Spataro
Disclosure:
Dr. Spataro has nothing to disclose.

5:30 PM 033 Wakeup Call: A Retrospective Study of "Miraculous" Coma Recoveries Eliezer Sternberg, MD
Disclosure:
Dr. Sternberg has nothing to disclose.

5:30 PM 034 Temporal Shifts of the Cerebral Autoregulation Curve in Comatose Patients with Acute Neurological Injury Julian Sanchez-Bautista
Disclosure:
Dr. Sanchez-Bautista has nothing to disclose.

5:30 PM 035 Comparison of hospital utilization, hospital mortality and length of stay for patients in persistent vegetative state across different racial groups Darine Kassar, MD
Disclosure:
Dr. kassar has nothing to disclose.

5:30 PM 036 Resilience, Cognitive Reserve and Brain Reserve in Neurocritical Care: A Prospective Cohort Study Neha Dangayach, MD
Disclosure:
Dr. Dangayach has nothing to disclose.

5:30 PM 037 Novel quantitative imaging markers for understanding cognitive reserve in subdural hematoma (SDH) patients Neha Dangayach, MD
Disclosure:
Dr. Dangayach has nothing to disclose.

Neurocritical Care: Ischemic Injury
Start Time Pub. Title Presenter
5:30 PM 038 Improving Neurologist Responsiveness For Telestroke Consultations: We Do Better! Jeffrey Wagner, MD
Disclosure:
Dr. Wagner has received personal compensation for activities with Genentech as a speaker.

5:30 PM 039 Influence of Neurologic Findings on the Early Transition to Less Aggressive Goals of Care after Cardiac Arrest Glenn Schubert
Disclosure:
Dr. Schubert has nothing to disclose.

5:30 PM 040 Characteristics of acute unconsciousness with basilar artery (BA) occlusion Hiroki Takano, MD
Disclosure:
Dr. Takano has nothing to disclose.

5:30 PM 041 Acute Kidney Injury in Acute Stroke. A preliminary study in Hispanic population Leticia Alejandra Olguín-Ramírez
Disclosure:
Dr. Olguín-Ramírez has nothing to disclose.

5:30 PM 042 EEG Can Be a Useful Tool in Predicting Outcome in Patients with Post Cardiac Arrest Clinical Myoclonus Omar Danoun, MD
Disclosure:
Dr. Danoun has nothing to disclose.

5:30 PM 043 Isolated bilateral globus pallidus infarcts in a patient with aortic dissection and Nitroprusside-induced hypotension: A case report Megan Esch, MD
Disclosure:
Dr. Esch has nothing to disclose.

5:30 PM 044 National trends in utilization of Intravenous thrombolysis and endovascular treatment in acute ischemic stroke Rakesh Khatri, MD
Disclosure:
Dr. Khatri has nothing to disclose.

5:30 PM 045 Feasibility of Near Infra-Red Spectroscopy in Blood Pressure Management Following Thrombectomy for Acute Large Vessel Occlusion Ischemic Stroke Vasu Saini, MD
Disclosure:
Dr. Saini has nothing to disclose.

5:30 PM 046 A Case of Spice use with Subsequent Withdrawal and Posterior Reversible Encephalopathy Syndrome (PRES) Christopher Stack, MD
Disclosure:
Dr. Stack has nothing to disclose.

5:30 PM 047 Evaluation of a Novel Noninvasive Cerebral Perfusion Monitor (C-Flow) After Cardiac Arrest Charles Francoeur
Disclosure:
Dr. Francoeur has nothing to disclose.

5:30 PM 048 Comparative analysis of in-hospital outcomes between spontaneous vertebral and carotid arterial dissection at National level Ihtesham Qureshi, MD
Disclosure:
Dr. Qureshi has nothing to disclose.

Neurocritical Care: Intracerebral Hemorrhage
Start Time Pub. Title Presenter
5:30 PM 049 International Normalized Ratio (INR) Reversal in Oral Anticoagulant-Associated Intracerebral Hemorrhage Fernando Testai, MD, PhD
Disclosure:
Dr. Testai has nothing to disclose.

5:30 PM 050 : Herpes simplex virus (HSV) encephalitis presenting as spontaneous intracerebral hemorrhage (ICH) chitra Sivasankar
Disclosure:
Dr. Sivasankar has nothing to disclose.

5:30 PM 051 Differences between the modified rankin scale and barthel index in measuring intracerebral hemorrhage recovery at 12 months. Anirudh Sreekrishnan
Disclosure:
Dr. Sreekrishnan has nothing to disclose.

5:30 PM 052 Neuroscience Intensive Care Unit Non-Admission Criteria (ICH-NIAC) for Patients with Intracerebral Hemorrhage Ayham M. Alkhachroum, MD
Disclosure:
Dr. Alkhachroum has nothing to disclose.

5:30 PM 053 Treatment Patterns and Outcomes of Patients Receiving Direct Oral Anticoagulants or Low Molecular Weight Heparin who Experienced Life-threatening Intracranial Hemorrhage Truman J. Milling
Disclosure:
Dr. Milling has received personal compensation for activities with CSI Behring, Janssen, BI, and Portola.

5:30 PM 054 Reversal of Anticoagulation Effects of Rivaroxaban and Associated Bleeding in a Rabbit Acute Hemorrhage Model by Andexanet Alfa vs. Coagulation Replacement Factors Genmin Lu
Disclosure:
Dr. Lu has received personal compensation for activities with Portola as an employee.

5:30 PM 055 Weight-based activated prothrombin complex concentrate (FEIBA) is better than FFP alone for hematoma expansion in patients with warfarin-induced intracranial hemorrhage Zakhar Serkin, MD
Disclosure:
Dr. Serkin has nothing to disclose.

5:30 PM 056 Insular DWI Hyperintensities in Subdural Hematoma: A case series and pathophysiologic review Daniel Sacchetti, DO
Disclosure:
Dr. Sacchetti has nothing to disclose.

5:30 PM 057 Association between Leukocyte Count and Perihematomal Edema Growth After Primary Intracerebral Hemorrhage Aaron Gusdon, MD
Disclosure:
Dr. Gusdon has nothing to disclose.

5:30 PM 058 The Influence of Changes in Barometric Pressure on the Occurrence of Primary Spontaneous Intracerebral Hemorrhage Vishal Pandya, MD
Disclosure:
Dr. Pandya has nothing to disclose.

5:30 PM 059 Andexanet Alfa for the Management of Acute Major Bleeding Associated with FXa Inhibitors Stuart J. Connolly
Disclosure:
Dr. Connolly has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals as a consultant.

5:30 PM 060 Pre-existing renal failure increases In-hospital mortality in Patients with Intracerebral hemorrhage Mohammad Rauf-Afzal
Disclosure:
Dr. Afzal has nothing to disclose.

5:30 PM 061 Hemorrhagic Stroke Patients Who Underwent EVD: Contemporary Mortality Trends in the National Inpatient Sample (NIS) Gwendolyn Lynch MD
Disclosure:
Dr. Lynch, MD has nothing to disclose.

5:30 PM 062 Circadian Rhythm Disruption and Severity of Impaired Arousal after Intracranial Hemorrhage Matthew Maas, MD
Disclosure:
Dr. Maas has received personal compensation for activities with Hyperfine Research, Inc., as a consultant.

5:30 PM 063 Prompt transition from intravenous nicardipine to oral antihypertensives reduces resource utilization for patients with hypertensive intracerebral hemorrhage. Omer Khayali
Disclosure:
Dr. Khayali has nothing to disclose.

Neurocritical Care: Subarachnoid Hemorrhage
Start Time Pub. Title Presenter
5:30 PM 064 SNO-Hb Levels Are Reduced in Patients with Subarachnoid Hemorrhage Ayham M. Alkhachroum, MD
Disclosure:
Dr. Alkhachroum has nothing to disclose.

5:30 PM 065 Volume of intracranial blood is associated with occurrence of stress induced hyperglycemia after aneurysmal subarachnoid hemorrhage Stephen Ross, MD
Disclosure:
Dr. Ross has nothing to disclose.

5:30 PM 066 Efficacy of cilostazol in prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized clinical trials Hamidreza Saber, MD
Disclosure:
Dr. Saber has nothing to disclose.

5:30 PM 067 Selective Frontal Lobe Metabolic Dysfunction after Subarachnoid Hemorrhage - Evidence for Flow-Metabolism uncoupling? Halinder Mangat, MD
Disclosure:
Dr. Mangat has nothing to disclose.

5:30 PM 068 Elevated ventricular CSF lactate within the first week after aneurysmal subarachnoid hemorrhage is associated with poor outcome Jackie Renfrow
Disclosure:
Dr. Renfrow has nothing to disclose.

5:30 PM 069 Does Intra-ICU Initiation of Guided Mindfulness Meditation Decrease Anxiety and Depression in SAH?: A Unique Methodology for the Neurocritical Care Setting Danielle S. Wheelwright
Disclosure:
Dr. Wheelwright has nothing to disclose.

5:30 PM 070 To be or not to be: Delirium screening for aneurysmal subarachnoid hemorrhage patients Nicholas Panos
Disclosure:
Dr. Panos has nothing to disclose.

Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time Pub. Title Presenter
5:30 PM 071 Understanding the use of noninvasive ventilation in the treatment of amyotrophic lateral sclerosis in the US and Europe: results of an international physician survey Terry Heiman-Patterson
Disclosure:
Cytokinetics: serve on scientific advisory board, consulting MT Pharma: Advisory board.

5:30 PM 072 Serial nerve ultrasound in paediatric Guillian-Barre Syndrome Ian Woodcock
Disclosure:
Dr. Woodcock has nothing to disclose.

5:30 PM 073 Myasthenia gravis after hematopoietic stem cell transplantation: A comprehensive review Jose David Avila, MD
Disclosure:
Dr. Avila has nothing to disclose.

5:30 PM 074 Unraveling disease burden in familial ALS due to SOD1 mutation through the combination of brain and cervical cord MRI Edoardo G. Spinelli, MD
Disclosure:
Dr. Spinelli has nothing to disclose.

5:30 PM 075 CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA) Rocio Garcia-Santibanez, MD
Disclosure:
Dr. Garcia-Santibanez has nothing to disclose.

5:30 PM 076 Assessment of corticospinal tract dysfunction and disease severity in amyotrophic lateral sclerosis. Rahul Remanan, MBBS
Disclosure:
Dr. Remanan has nothing to disclose.

5:30 PM 077 Mitochondrial Skeletal and Cardiac Myopathy Responsive to Aggressive Immunosuppression in Rapidly Progressing Systemic Sclerosis Crystal Yeo, MD, PhD
Disclosure:
Dr. Yeo has nothing to disclose.

5:30 PM 078 Ultrasound Diagnosis of a Median Nerve Penetration by a Peripherally Inserted Central Catheter (PICC) Line Arjumond Khan
Disclosure:
Dr. Khan has nothing to disclose.

5:30 PM 079 A treatment classifier for long-term follow-up of intravenous immunoglobulin therapy response. Rahul Remanan, MBBS
Disclosure:
Dr. Remanan has nothing to disclose.

5:30 PM 080 Quantification of intramuscular blood flow with power Doppler ultrasonography in patients with small fiber neuropathy Wei Ping Kay Ng, MD
Disclosure:
Dr. Ng has nothing to disclose.

Aging and Dementia: Other
Start Time Pub. Title Presenter
5:30 PM 081 Alzheimer’s Care Via Telemedicine for Oregon (ACT-ON), Phase II: A Pilot Study of to-the-Home Dementia Care Via Telemedicine Deniz Erten-Lyons, MD
Disclosure:
Dr. Erten-Lyons has received research support from Glaxo-Smith Kline.

5:30 PM 082 Diagnostic flowchart of adult-onset neuronal intranuclear inclusion disease Jun Sone, MD, PhD
Disclosure:
I have the endowed chair from Japan Blood Products Organization..

5:30 PM 083 Rapidly Progressive Dementia in the Outpatient Clinic: More than Prions Gregory S Day, MD, MSc
Disclosure:
Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health) and MedEdicus.. Dr. Day holds stock and/or stock options in ANI Pharmaceuticals (a generic pharmaceutical company).. Dr. Day has received research support from Avid Radiopharmaceuticals (a wholly-owned subsidiary of Eli Lilly)..

5:30 PM 084 A Clinical Registry of Rapidly Progressive Dementia in Argentina: Towards a More Accurate Diagnosis of Autoimmune Dementias Galeno Rojas
Disclosure:
Dr. Rojas has nothing to disclose.

5:30 PM 085 Rapidly Progressive Dementia: A retrospective cohort study from a tertiary care hospital Anuja Patil
Disclosure:
Dr. Patil has nothing to disclose.

5:30 PM 086 Aerosol Exposure to Cyanobacteria as a Potential Risk Factor for Neurological Disease Patricia Henegan
Disclosure:
Dr. Henegan has nothing to disclose.

Aging and Dementia: Model Systems
Start Time Pub. Title Presenter
5:30 PM 087 Synthetic Metalloporphyrins and Resveratrol act synergistically as enhancers of cognitive performance through reduction of deposited amyloid beta and improvement of mitochondrial function in Alzheimer's mice. Natasa Dragicevic MD PhD
Disclosure:
Dr. Dragicevic MD PhD has nothing to disclose.

5:30 PM 088 Mechanisms linking amyloid ß and tau pathologies in neurons Xiang Bai
Disclosure:
Dr. Bai has nothing to disclose.

5:30 PM 089 The anti-aging factor GDF11 has both direct and indirect effects on mouse neural stem cells Richard Krolewski, MD
Disclosure:
Dr. Krolewski has nothing to disclose.

5:30 PM 090 Rodent models of delirium and encephalopathy: Behavioral and neurophysiological studies in aging Eyal Kimchi, MD, PhD
Disclosure:
Dr. Kimchi has nothing to disclose.

5:30 PM 091 Electrical impedance myography identifies age-associated changes in mouse gastrocnemius msucle Rebecca Taylor
Disclosure:
Dr. Taylor has nothing to disclose.

5:30 PM 093 The synergy between brain amyloidosis and hypometabolism on cognitive decline in humans and transgenic amyloid rats Tharick A. Pascoal
Disclosure:
Dr. Pascoal has nothing to disclose.

Aging and Dementia: Primary Progressive Aphasia
Start Time Pub. Title Presenter
5:30 PM 094 Alzheimer’s disease CSF profile in semantic variant of primary progressive aphasia and brain perfusion pattern Raffaella Migliaccio
Disclosure:
Dr. Migliaccio has nothing to disclose.

5:30 PM 095 Tau in the nonfluent variant of primary progressive aphasia: Network involvement Belen Pascual
Disclosure:
Dr. Pascual has nothing to disclose.

5:30 PM 096 Anatomical Network Degeneration in Primary Progressive Aphasia John Medaglia, PhD
Disclosure:
Dr. Medaglia has nothing to disclose.

5:30 PM 097 Comparison of hypometabolism and cortical atrophy in Primary Progressive Aphasia Katarzyna Adamczuk, PhD
Disclosure:
Dr. Adamczuk has nothing to disclose.

5:30 PM 098 Change in functional organization of the speech and language network in non-fluent/agrammatic variant PPA Maria Luisa Mandelli
Disclosure:
Dr. Mandelli has nothing to disclose.

5:30 PM 099 Greater frequency of APOE E4 in logopenic variant primary progressive aphasia Jessica Deleon, MD
Disclosure:
Dr. Deleon has nothing to disclose.

5:30 PM 100 NA NA NA
Disclosure:

Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session
Start Time Pub. Title Presenter
5:30 PM 101 Clinical and economical comparison of plasmapheresis and intravenous immunoglobulin in treating myasthenia gravis crisis: An analysis of 3808 cases from the Nationwide Inpatient Sample Leila Darki, MD
Disclosure:
Dr. Darki has nothing to disclose.

5:30 PM 102 A dedicated electrical impedance myography device in the assessment of Duchenne muscular dystrophy. Craig Zaidman, MD
Disclosure:
Dr. Zaidman has nothing to disclose.

5:30 PM 103 Sonomorphology in relation to functional changes in treatment-naive chronic inflammatory demyelinating polyneuropathy: is it a continuum or spectrum of pathology? Stephan Goedee, MD
Disclosure:
Dr. Goedee has nothing to disclose.

5:30 PM 104 Electrical Impedance Myography (EIM) studies in subjects with C9ORF72 gene mutation Michelle Offit M.S.
Disclosure:
Dr. Offit, M.S. has nothing to disclose.

5:30 PM 105 Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) FJ Schnell
Disclosure:
Dr. Schnell has received personal compensation for activities with Sarepta Therapeutics as a full time employee.

5:30 PM 106 The Effect of Bariatric Surgery on Peripheral Nerve Regeneration Joshua Winegar
Disclosure:
Dr. Winegar has nothing to disclose.

5:30 PM 107 Increased EEG theta spectral power in polysomnography of myotonic dystrophy type 1 compared to matched controls. Chad Ruoff
Disclosure:
Dr. Ruoff has received personal compensation for activities with Jazz Pharmaceuticals as a scientific advisory board member.

5:30 PM 108 Selective network degeneration in ALS: a connectivity-based analysis of frontostriatal and cortico-basal circuitry Peter Bede, MD
Disclosure:
Dr. Bede has nothing to disclose.

5:30 PM 109 Laser microdissection and proteomic analysis in the tubular aggregates myopathy. A preliminary study. Andre Maues De Paula
Disclosure:
Dr. Maues De Paula has nothing to disclose.

5:30 PM 110 Cumulative Distribution of Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) Scores in a Phase 3 Study of Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment Koji Takei
Disclosure:
Dr. Takei has received personal compensation for activities with Mitsubishi Tanabe as an employee.

Neuromuscular and Clinial Neurophysiology (EMG): Peripheral Neuropathy II
Start Time Pub. Title Presenter
5:30 PM 111 Ganglioside composite testing identifies immune responsive motor-onset MADSAM and MMN Jennifer Martinez-Thompson, MD
Disclosure:
Dr. Martinez-Thompson has nothing to disclose.

5:30 PM 112 Chemical Neuro Stimulation by FLX-787, a co-activator of TRPA1/TRPV1, for the Potential Treatment of Cramps, Spasms and Spasticity Glenn Short
Disclosure:
Dr. Short has received personal compensation for activities with Flex Pharma. Dr. Short hold stock and/or stock options in Flex Pharma.

5:30 PM 113 Molecular mechanisms of age-dependent painful polyneuropathy in metabolic syndrome Joe Ward
Disclosure:
Dr. Ward has nothing to disclose.

5:30 PM 114 Predictors of motor recovery in pediatric Acute Inflammatory Demyelinating Polyneuropathy Jennifer Choi, MD
Disclosure:
Dr. Choi has nothing to disclose.

5:30 PM 115 Cranial Neuropathy in patients with Peripheral Nerve Disorders. Edrich Rodrigues, MBBChB
Disclosure:
Dr. Rodrigues has nothing to disclose.

5:30 PM 116 Early onset Charcot-Marie-Tooth disease: Clinical and genetic spectrum in a Tunisian series Imen Kacem, MD
Disclosure:
Dr. Kacem has nothing to disclose.

5:30 PM 117 A population-based approach to chemotherapy-induced peripheral neuropathy reveals the disease burden of early and late effects Arya Shah
Disclosure:
Dr. Shah has nothing to disclose.

5:30 PM 118 Prediabetes does not cause small fiber neuropathy Pariwat Thaisetthawatkul, MD
Disclosure:
Dr. Thaisetthawatkul has nothing to disclose.

5:30 PM 119 Guillain-Barré Syndrome Related to Zika Virus Infection in Brazil Amilton Antunes Barreira
Disclosure:
Dr. Barreira has received personal compensation for activities with Baxter as a speaker and participant in an advisory board.

5:30 PM 120 Recombinant cell-based indirect immunofluorescence assay for the detection of IgM paraproteins in polyneuropathy Rittika Chunder
Disclosure:
Dr. Chunder has received personal compensation for activities with EUROIMMUN AG as an employee.

5:30 PM 121 The Clinical Electrophysiologic and Pathologic Phenotype of Chemotherapy Induced Peripheral Neuropathy Summer Karafiath, MD
Disclosure:
Dr. Karafiath has nothing to disclose.

5:30 PM 122 Mitochondrial ND5 mutation: neurological improvement after CoQ10 supplementation Jose Luiz Pedroso, MD
Disclosure:
Dr. Pedroso has nothing to disclose.

5:30 PM 123 Nerve conduction study of sensory and motor lower limb nerves in children with type 1 diabetes mellitus attending Sudan Childhood Diabetes Center Hana Ahmed
Disclosure:
Dr. Ahmed has nothing to disclose.

5:30 PM 124 Diagnostic Challenges due to Atypical presentations of CMT in Charcot Marie Tooth Disease type 4C associated with SH3TC2 mutations Nivedita Jerath, MD
Disclosure:
Dr. Jerath has nothing to disclose.

5:30 PM 125 Case Control Analysis of Glycine Receptor Autoimmunity Alfonso Sebastian Lopez-Chiriboga, MD
Disclosure:
Dr. Lopez has nothing to disclose.

5:30 PM 126 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER): Study design and progress update Jeffrey Allen, MD
Disclosure:
Dr. Allen has nothing to disclose.

5:30 PM 127 Acquired Neuromyotonia: Atypical Unique Features Monica Lavian, DO
Disclosure:
Dr. Lavian has nothing to disclose.

5:30 PM 128 Electrodiagnostic findings in pediatric patients with winged scapula Rajesh Gupta
Disclosure:
Dr. Gupta has nothing to disclose.

5:30 PM 129 Clinical and electrodiagnostic correlations of paraproteinemic neuropathies Annie Daniel, MBBS
Disclosure:
Dr. Daniel has nothing to disclose.

5:30 PM 130 Structural and Functional Tests of Neuropathy in Diabetes Christopher Gibbons, MD, FAAN
Disclosure:
Dr. Gibbons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck Inc.. Dr. Gibbons has received research support from Grifols Inc..

5:30 PM 131 Abnormal voltage-gated Na+ ion-channel function in regenerated motor fibers of aged mice Christian Krarup, MD, DMSc, FRcP
Disclosure:
Dr. Krarup has received personal compensation for activities with Integra LifeSciences and Abbott as a speaker and/or advisor. Dr. has received research support from Integra LifeSciences and Shire HGT.

5:30 PM 132 Inflammatory diabetic neuropathy: helpful diagnostic parameters Pariwat Thaisetthawatkul, MD
Disclosure:
Dr. Thaisetthawatkul has nothing to disclose.

5:30 PM 133 Clinical and Laboratory Profiles of Small Fiber Neuropathy In Children: Case Series Ali Al Balushi, MD
Disclosure:
Dr. Al Balushi has nothing to disclose.

5:30 PM 134 Charcot-Marie-Tooth Disease in Turkey: Clinical and Genetic Findings from a Single-centre Experience Halil Ibrahim Akcay
Disclosure:
Dr. Akcay has nothing to disclose.

5:30 PM 135 Assessment of Neurologists Practice Patterns for Chronic Inflammatory Demyelinating Polyneuropathy: Perspectives on Diagnosis and Management Thomas Finnegan
Disclosure:
Dr. Finnegan has nothing to disclose.

5:30 PM 136 Coenzyme Q deficiency causes impairment of the sulfide oxidation pathway Marcello Ziosi
Disclosure:
Dr. Ziosi has nothing to disclose.

5:30 PM 137 Guillain-Barré Syndrome Trend of Hospital Length of Stay, Complication Rate and Mortality Depending from Method of the Treatment: IVIg vs. PLEX Alexander Gevorgyan M.D. Ph.D., MD
Disclosure:
Dr. Gevorgyan, M.D., Ph.D. has nothing to disclose.

5:30 PM 138 Identification of the CNTN1/CASPR complex as the target of autoantibodies in a patient with chronic inflammatory demyelinating polyneuropathy Stephanie Kade
Disclosure:
Dr. Kade has received personal compensation for activities with Euroimmun AG as an employee.

5:30 PM 139 A Rare Cause of Rapidly Progressive Acute Motor Axonal Polyradiculoneuropathy Bhavana Sharma, MD
Disclosure:
Dr. Sharma has nothing to disclose.

5:30 PM 140 Contact Heat Evoked Potential in normal subjects: is there any disparity among different Centers? Fernanda Herculano
Disclosure:
Dr. Herculano has nothing to disclose.

5:30 PM 141 Neurolymphomatosis: A review of 82 cases Jose David Avila, MD
Disclosure:
Dr. Avila has nothing to disclose.

5:30 PM 142 Peripheral neuropathies after bariatric surgery: Kuwait experience Jasem Al Hashel
Disclosure:
Dr. Al Hashel has nothing to disclose.

5:30 PM 143 NA NA NA
Disclosure:

5:30 PM 144 NA NA NA
Disclosure:

Clinical Neuro-rehabilitation
Start Time Pub. Title Presenter
5:30 PM 145 Sex Disparities in Discharge Ambulation Status after Acute Ischemic Stroke: The Florida-Puerto Rico Collaboration to Reduce Stroke Disparities (FL-PR CReSD) Sofia Oluwole
Disclosure:
Dr. Oluwole has nothing to disclose.

5:30 PM 146 Promoting network recovery after traumatic brain injury: exploring the targeted application of transcranial direct current stimulation Lucia M Li
Disclosure:
Dr. Li has nothing to disclose.

5:30 PM 147 Increased Prevalence of Early Post Stroke Depression Among Single Women after Ischemic Stroke. Phillip Kucab
Disclosure:
Dr. Kucab has received personal compensation for activities with National Hemophilia Foundation as a consultant.

5:30 PM 148 National Estimates of Recurrent Intracranial Hemorrhage among Patients with Ruptured Intracranial Aneurysms: Effect of Treatment Modality Adnan Qureshi
Disclosure:
Dr. Qureshi has nothing to disclose.

5:30 PM 149 Characterization of pain and fatigue following deployment-related mild traumatic brain injury Jeffrey Lewis, MD PhD
Disclosure:
Dr. Lewis has nothing to disclose.

5:30 PM 150 Ultra-early Institution of Statin Treatment is Associated with Improved Outcomes Among Acute Ischemic Stroke Patients Receiving Thrombolytic Treatment Muhammad Saleem
Disclosure:
Dr. Saleem has nothing to disclose.

5:30 PM 151 Transcranial Direct Current Stimulation in Post-Stroke Aphasia Rehabilitation: Bilateral vs Unilateral Online Stimulation Angelo Torrente
Disclosure:
Dr. Torrente has nothing to disclose.

5:30 PM 152 Prevalence of insomnia among stroke survivors in United States: Analysis of National Health and Nutrition Examination Surveys 2005 to 2008. Sher Afgan
Disclosure:
Dr. Afgan has nothing to disclose.

5:30 PM 153 A pilot study to examine the effects of a multimodal sensory stimulation protocol for unilateral spatial neglect rehab in subacute MCA stroke Janet Ayad
Disclosure:
Dr. Ayad has nothing to disclose.

5:30 PM 154 Lower urinary tract symptoms and sexual dysfunction in patients with multiple sclerosis Katarina Ivana Tudor
Disclosure:
Dr. Tudor has received personal compensation for activities with Medtronic and Fresenius Kabi as a speaker.

5:30 PM 155 Is erectile dysfunction more frequent among men with history of stroke: Analysis of National Health and Nutrition Examination Surveys 2001 to 2004 Sher Afgan
Disclosure:
Dr. Afgan has nothing to disclose.

5:30 PM 156 Evaluation of possible role of repetitive transcranial magnetic stimulation for dysphagic patients with brain stem infarction. Elsayed tageldin
Disclosure:
Dr. tageldin has nothing to disclose.

5:30 PM 157 Harmonizing Together: Speech and Music Therapy and Support for Patients and Partners with PPA Megan Quimby
Disclosure:
Dr. Quimby has received personal compensation for activities with Massachusetts General Hospital as an employee.

5:30 PM 158 Posterior Reversible Encephalopathy Syndrome Triggered by Autonomic Dysreflexia in a Spinal Cord Injury Patient Salman Farooq, MD
Disclosure:
Dr. Farooq has nothing to disclose.

5:30 PM 159 Cerebral FDG-PET Findings in Patients with Traumatic Disorders of Consciousness: Preliminary Results of a Pilot Study Lisandro Olmos
Disclosure:
Dr. Olmos has nothing to disclose.

Neuro-oncology: Gliomas II
Start Time Pub. Title Presenter
5:30 PM 160 Cerebellar Diffuse Midline Glioma, H3 K27M-Mutant in an Adult Patient: Case Report Zachary Craig
Disclosure:
Dr. Craig has nothing to disclose.

5:30 PM 161 Concurrent diagnosis of glioblastoma (GBM), neuromyelitis optica (NMO) spectrum disorder and Progressive Multifocal Leukoencephalopathy (PML): imaging, pathology, and clinical course. Laura Donovan, MD
Disclosure:
Dr. Donovan has nothing to disclose.

5:30 PM 163 Primary and secondary gliosarcomas: clinical profile and outcomes at the National Cancer Institute Surabhi Ranjan
Disclosure:
Dr. Ranjan has nothing to disclose.

5:30 PM 164 A Clinical, Radiologic, and Pathologic Review of Astroblastoma: The MD Anderson Experience Jooyeon Nam, MD
Disclosure:
Dr. Nam has nothing to disclose.

5:30 PM 165 Advanced head models to improve TMS-based motor cortex localization Laura Seynaeve
Disclosure:
Dr. Seynaeve has nothing to disclose.

5:30 PM 166 Negative navigated transcranial magnetic stimulation mapping in a patient with preoperative lower extremity weakness: A case report Bhanu Gogia, MD
Disclosure:
Dr. Gogia has nothing to disclose.

5:30 PM 167 Bevacizumab: is the lower the better for glioblastoma patients in progression? Lila Sirven-Villaros
Disclosure:
Dr. Sirven-Villaros has nothing to disclose.

5:30 PM 168 Creation of a multicenter glioblastoma ontology database: A therapy-guided analysis of genotype to phenotype relationships Evan Noch, MD
Disclosure:
Dr. Noch has nothing to disclose.

5:30 PM 169 Tumor Treating Fields Distribution in Glioblastoma Volume Depends on Conductivity Parameters Edwin Lok
Disclosure:
Dr. Lok has nothing to disclose.

Neuro-oncology: Brain and CNS Metastases
Start Time Pub. Title Presenter
5:30 PM 170 Cerebrospinal Fluid Circulating Tumor Cells: A Novel Tool to Diagnose Leptomeningeal Metastases from Epithelial Tumors Xuling Lin, MD
Disclosure:
Dr. Lin has nothing to disclose.

5:30 PM 171 Breast Cancer Brain Metastases Alter Chemokine and Cytokine Profiles in the Cerebrospinal Fluid Johnson Fong
Disclosure:
Dr. Fong has nothing to disclose.

5:30 PM 172 DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy Yoshie Umemura, MD
Disclosure:
Dr. Umemura has nothing to disclose.

5:30 PM 173 Recurrent breast cancer presenting with indolent peripheral nerve metastases mimicking chronic inflammatory neuropathies: two cases. Aditya Vuppala, MD
Disclosure:
Dr. Vuppala has nothing to disclose.

5:30 PM 174 Response of melanoma brain metastases to ipilimumab: a retrospective review. Nancy Wang, MD
Disclosure:
Dr. Wang has nothing to disclose.

5:30 PM 175 Are lateral cervical punctures under-utilized? Yoshie Umemura, MD
Disclosure:
Dr. Umemura has nothing to disclose.

5:30 PM 176 Vismodegib Treatment of Intracranial Invasion of Basal Cell Carcinoma Evan Jameyfield
Disclosure:
Dr. Jameyfield has nothing to disclose.

5:30 PM 177 Clinical Profile and Factors Affecting Survival in Leptomeningeal Carcinomatosis Aashrai Gudlavalleti
Disclosure:
Dr. Gudlavalleti has nothing to disclose.

5:30 PM 178 CNS Recurrence of AML Presenting as Cerebellitis Edward Boyer, MD
Disclosure:
Dr. Boyer has nothing to disclose.

5:30 PM 179 Leptomeningeal Myelomatosis as a rare Neurologic complication of Multiple Myeloma. Mina Lobbous, MD
Disclosure:
Dr. Lobbous has nothing to disclose.

5:30 PM 180 Seeing double: Trigeminal neurotropic melanoma as primary recurrence site, presenting as diplopia. Neil Datta, MD
Disclosure:
Dr. Datta has nothing to disclose.

5:30 PM 181 Pancreatic Cancer with Leptomeningeal Carcinomatosis: Case Presentation and Literature Review Adriana Sofia Perilla
Disclosure:
Dr. Perilla has nothing to disclose.

5:30 PM 182 Isolated Facial Nerve Palsy Secondary to Temporal Bone Metastasis Sangeetha Poongunam Isaac
Disclosure:
Dr. Isaac has nothing to disclose.

5:30 PM 183 A Rare Neurological Complication of Waldenstrom’s Macroglobulinemia Gabriel Torrealba Acosta
Disclosure:
Dr. Torrealba Acosta has nothing to disclose.

Neuro-ophthalmology/Neuro-otology I
Start Time Pub. Title Presenter
5:30 PM 184 Unilateral Optic Neuritis And Retinal Vasculitis Due To Ocular Syphilis Dulanji Kuruppu
Disclosure:
Dr. Kuruppu has nothing to disclose.

5:30 PM 185 Unilateral papilledema in idiopathic intracranial hypertension: a report of two cases and literature review Emily Swinkin, MD
Disclosure:
Dr. Swinkin has nothing to disclose.

5:30 PM 186 Oculomotor nerve palsy by non-aneurysm vascular compression Sungyang Jo
Disclosure:
Dr. Jo has nothing to disclose.

5:30 PM 187 Isolated Inferior Rectus Palsy as the Solitary Manifestation of Thiamine Deficiency in Patient with Diplopia Mary-Ann Fares, MD
Disclosure:
Dr. Fares has nothing to disclose.

5:30 PM 188 OPTIC NEURITIS DURING PREGNANCY FOLLOWING Tdpa VACCINATION: REPORT OF TWO CASES. Jose Maria Cabrera Maqueda
Disclosure:
Dr. Cabrera Maqueda has nothing to disclose.

5:30 PM 189 Castleman disease with follicular dendritic cell sarcoma presenting with pseudotumor cerebri and myasthenia gravis Alexander Fein
Disclosure:
Dr. Fein has nothing to disclose.

5:30 PM 190 Ophthalmic findings in a Hunter Syndrome patient on enzyme replacement therapy Allison Jarstad
Disclosure:
Dr. Jarstad has nothing to disclose.

5:30 PM 191 Hemodynamic neuro-ophthalmic complications from hemodialysis Nailyn Rasool, MD
Disclosure:
Dr. Rasool has nothing to disclose.

5:30 PM 192 Convergence spasm in Wernicke's encephalopathy Syed Shabbir, MD
Disclosure:
Dr. Shabbir has nothing to disclose.

5:30 PM 193 Vestibulocochlear nerve dysfunction as initial manifestation of Waldenstrom Macroglobulinemia Mohammad Humayun, MD
Disclosure:
Dr. Humayun has nothing to disclose.

5:30 PM 194 Vision Loss with Symmetric Putaminal Lesions in Leber's Hereditary Optic Neuropathy Matthew Mercuri, MD
Disclosure:
Dr. Mercuri has nothing to disclose.

5:30 PM 195 Swallow-Induced Eyelid Myokymia: A Novel Synkinesis Syndrome Amrita-Amanda Lakraj, MD
Disclosure:
Dr. Lakraj has nothing to disclose.

5:30 PM 196 CSF Protein in Patients with Idiopathic Intracranial Hypertension (IIH) Damian Berezovsky, MD
Disclosure:
Dr. Berezovsky has nothing to disclose.

5:30 PM 197 Diffusion-weighted MRI finding associated with retinal deficits. Omar Alsinaidi
Disclosure:
Dr. Alsinaidi has nothing to disclose.

5:30 PM 198 Uhthoff Phenomenon and Associated Factors in a Series of Optical Neuritis Estefanía García Molina
Disclosure:
Dr. García Molina has nothing to disclose.

5:30 PM 199 High dose intravenous steroids as first line treatment for severe idiopathic sudden sensorineural hearing loss Sue Faye Siow, MBBS
Disclosure:
Dr. Siow has nothing to disclose.

5:30 PM 200 Comparison Study of Ocular Fundus Examination of Pediatric Patients Using the D-EYE device and Conventional Indirect Ophthalmoscopy samiksha fouzdar jain
Disclosure:

5:30 PM 201 Optical Coherence Tomography, full-field Visual Evoked Potentials and multifocal Visual Evoked Potentials to monitor and predict Optic Nerve damage and Clinical Outcome after Acute Optic Neuritis in Clinical Practice. Simone Guerrieri
Disclosure:
Dr. Guerrieri has nothing to disclose.

5:30 PM 202 Dalfampridine Treatment in Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Mark Moster, MD, FAAN
Disclosure:
Dr. Moster has nothing to disclose.

5:30 PM 203 Papilledema from Compression of Intracranial Venous Sinuses by Dural Meningiomas Alexander Hartmann
Disclosure:
Dr. Hartmann has nothing to disclose.

5:30 PM 204 Close encounter on chromosome 14 Sergiu Blumen
Disclosure:
Dr. Blumen has nothing to disclose.

5:30 PM 205 Identifying correlations between fluoroscopy-guided lumbar puncture and subsequent low-pressure syndrome in pseudotumor cerebri patients Patricia Lu
Disclosure:
Dr. Lu has nothing to disclose.

Neuro Trauma and Sports Neurology I
Start Time Pub. Title Presenter
5:30 PM 206 Longitudinal Recovery of Cerebrovascular Impairment Following Sports Related Concussion Utilizing Transcranial Doppler Corey M. Thibeault
Disclosure:
Dr. Thibeault holds stock and/or stock options in Neural Analytics as an employee. Dr. Thibeault has received research support from Neural Analytics.

5:30 PM 207 Magnetic Resonance Spectroscopic Imaging at 7T (7T MRSI) abnormalities in Veterans with PTSD and mild TBI (mTBI) Anne Van Cott, MD, FAAN
Disclosure:
Dr. Van Cott has nothing to disclose.

5:30 PM 208 Association Between Concussion and Lower Extremity Injuries in Collegiate Athletes Thomas Buckley, PhD
Disclosure:
......Research contract with Applied Cognitive Engineering. Received research funding, including salary support, for performing a study on their product - Intelligym

5:30 PM 209 The relationship between transcranial Doppler ultrasound measured pulsatility index and P2 ratio of the middle cerebral artery after sports related concussion Samuel Thorpe
Disclosure:
Employee of Neural Analytics....Employee of Neural Analytics.Employee of Neural Analytics.Neural Analytics Employee

5:30 PM 210 History of Concussion does not Adversely Affect Static Postural Control in Youth Ice Hockey Athletes Jessie Oldham
Disclosure:
Dr. Oldham has nothing to disclose.

5:30 PM 211 Concussion Awareness Program in High School Football Players and Coaches Anthony Martino
Disclosure:
......NCAA Mind Matters Challenge Grant

5:30 PM 212 Effects of Exercise on SCAT-3 Performance in Amateur Female Athletes Andrew Gardner
Disclosure:
Dr. Gardner has nothing to disclose.

5:30 PM 213 Persistent dizziness after mild traumatic brain injury Ana Bisonni
Disclosure:
Dr. Bisonni has nothing to disclose.

5:30 PM 214 Sensorimotor Vision Screening in a Random Sample of Recently Deployed Soldiers With and Without a History of Mild TBI Amy Chang
Disclosure:
Dr. Chang has nothing to disclose.

5:30 PM 215 Between Trial Reliability of the King Devick Test Katherine Breedlove
Disclosure:
Dr. Breedlove has nothing to disclose.

5:30 PM 216 Preliminary Analysis of Head Impact Kinematics in Youth Ice Hockey Melissa DiFabio
Disclosure:

5:30 PM 217 Discordance between Documented Criteria for TBI and Written Emergency Department Diagnosis of TBI Neekita Jikaria
Disclosure:
Dr. Jikaria has nothing to disclose.

5:30 PM 218 Building the Four Corners Youth Consortium (4CYC) for Brain Health in Youth Sports and Recreation Meeryo Choe, MD
Disclosure:
......Current funding includes a NIH/SBIR grant with Neural Analytics investigating the use of Doppler ultrasound after concussion to evaluate cerebral blood flow and cerebrovascular reactivity.

5:30 PM 219 Utility of high-sensitivty C Reactive Protein as Biomarker for Concussion Teena Shetty
Disclosure:
Dr. Teena has received personal compensation for activities with GE-NFL as a medical advisory board member. Dr. Teena has received research support from GE-NFL, Chembio, and Abbott.

5:30 PM 220 Year to Year Reliability of the King Devick Test in Collegiate Student-Athletes: An NCAA/DoD Grand Alliance Report. Thomas Buckley, PhD
Disclosure:
......Research contract with Applied Cognitive Engineering. Received research funding, including salary support, for performing a study on their product - Intelligym

5:30 PM 221 Cis p-tau directly links traumatic brain injury with chronic traumatic encephalopathy and Alzheimer’s disease, but can be blocked by antibody Alexander Houck
Disclosure:
Kun Ping Lu and Xiao Zhen Zhou are scientific founders and consultants of Pinteon Therapeutics. Kun Ping Lu and Xiao Zhen Zhou are scientific founders and consultants of Pinteon Therapeutics.

Epilepsy and Clinical Neurophysiology: Clinical Epilepsy IV
Start Time Pub. Title Presenter
5:30 PM 223 Extreme delta brush in electroencephalogram may be nonspecific to the anti-NMDAR encephalitis. Kanako Namekawa
Disclosure:
Dr. Namekawa has nothing to disclose.

5:30 PM 224 Ictal heart rate in focal epilepsy: implicancies for the heart-brain association. Jose Molina Melendres
Disclosure:
Dr. Molina Melendres has nothing to disclose.

5:30 PM 225 Bone health screening in the Epilepsy Clinic James Bathe, MD
Disclosure:
Dr. Bathe has nothing to disclose.

5:30 PM 226 Tolerability of Lacosamide and Zonisamide in the treatment of elderly patients with epilepsy Johny Nicolas
Disclosure:
Dr. Nicolas has nothing to disclose.

5:30 PM 227 Efficacy of lacosamide monotherapy in patients with newly diagnosed epilepsy stratified by baseline disease severity: sub-analysis of data from a prospective non-inferiority trial versus controlled-release carbamazepine Manuel Toledo
Disclosure:
Dr. Toledo has received personal compensation for activities with UCB Pharma, BIAL, EISAI, Esteve, and Shire as a consultant. Dr. Toledo has received research support from EISAI and BIAL.

5:30 PM 228 Efficacy and tolerability of lacosamide monotherapy in patients with newly diagnosed epilepsy: A prospective randomized double-blind non-inferiority trial versus controlled-release carbamazepine Michel Baulac
Disclosure:
Dr Baulac received personal compensation for activities with EISAI, UCB, SAGE as a consultant and speaker. Dr Baulac has received research support from EISAI and UCB pharma.

5:30 PM 229 Tolerability and efficacy of lacosamide monotherapy in patients with newly-diagnosed epilepsy and psychiatric comorbidities: Post hoc analysis of a prospective, randomized, double-blind trial Bettina Schmitz
Disclosure:
Dr. Schmitz received personal compensation for activities with UCB Pharma, Desitin Pharma, and Eisai as a speaker. Dr. Schmitz received research support from UCB Pharma.

5:30 PM 230 Effectiveness of lacosamide monotherapy in clinical practice: a retrospective chart review in patients with focal seizures Vincente Villanueva
Disclosure:
Dr Villanueva has participated in advisory boards and pharmaceutical industry-sponsored symposia for Eisai, UCB, Bial, Novartis and Esteve. Dr Villanueva has received research support from for Eisai, UCB and Bial.

5:30 PM 231 Outcomes following exposure to the antiepileptic drug lacosamide during pregnancy - results from a global safety database Amanda Golembesky
Disclosure:
Employee of UCB Pharma,,,,I have stock or stock options as a full time employee of UCB Pharma,,

Dr. Golembesky has received personal compensation for activities with UCB as an employee. Dr. Golembesky holds stock and/or stock options in UCB Pharma which sponsored research in which Dr. Golembesky was involved as an investigator.

5:30 PM 232 Efficacy and tolerability of lacosamide monotherapy in elderly patients with newly diagnosed epilepsy: subgroup analysis of a non-inferiority trial versus controlled-release carbamazepine Felix Rosenow
Disclosure:
Dr. Rosenow has received personal compensation for activities with Sandoz, Hexal, EISAI GmbH, cerbomed, Bayer-Vital UCB Pharma, Desitin GmbH, Shire, and Novartis as a consultant or speaker.

5:30 PM 233 Long-term safety and efficacy outcomes of adjunctive perampanel: an open-label extension (OLEx) of a Phase III study in patients with drug-resistant primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized epilepsy (IGE) Robert T Wechsler, MD, PhD, FAAN
Disclosure:
Speaking: Eisai, Livanova, Lundbeck, Sunovion, UCB Consulting: Alexza, Eisai, Engage, Lundbeck, Sunovion, UCB, Upsher-Smith.

5:30 PM 235 Continuity of Care With IV Carbamazepine: A Case Report for Maintaining Treatment Martin J. Brodie
Disclosure:
Dr. Brodie has received personal compensation for activities with UCB Pharma, Eisai Ltd, Lundbeck Inc., GW Pharmaceuticals, Bial, GlaxoSmithKline, Sanofi Aventis, and Abbot for grants/research support, honoraria, consulting fees, or speakers bureau. Dr. Brodie has received research support from UCB Pharma.

5:30 PM 236 A multicenter, open-label trial of ganaxolone in children with PCDH19 epilepsy Jaakko Lappalainen
Disclosure:
Dr. Lappalainen has received personal compensation for activities with Marinus Pharmaceuticals as an employee. Dr. Lappalainen has received research support from Marinus Pharmaceuticals.

5:30 PM 237 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Focal-Onset Seizures Jaakko Lappalainen
Disclosure:
Dr. Lappalainen has received personal compensation for activities with Marinus Pharmaceuticals as an employee. Dr. Lappalainen has received research support from Marinus Pharmaceuticals.

5:30 PM 238 Bioequivalence and Safety Profiles of a Novel, Extended-Release, High-Dosage Formulation of Levetiracetam in Healthy Adult Subjects Yashoraj Zala
Disclosure:
Dr. Zala has nothing to disclose.

5:30 PM 239 Majority of Epileptic Marijuana Users Perceive Decreased Seizure Frequency Ruby Upadhyay, MD
Disclosure:
Dr. Upadhyay has nothing to disclose.

5:30 PM 240 Burden Of Recreational And Prescription Drugs Substance Abuse In Epilepsy And Seizure Hospitalizations. Urvish Patel
Disclosure:
Dr. Patel has nothing to disclose.

5:30 PM 241 Modified ketogenic diets are likely the best option for the most refractory epilepsy patients—those who have failed epilepsy surgery Jessica Falco-Walter
Disclosure:
Dr. Falco-Walter has nothing to disclose.

5:30 PM 242 Do certain groups respond better to modified ketogenic diet treatments? Evaluation of adults based on imaging abnormalities, seizure type, and diet type Jessica Walter
Disclosure:
Dr. Falco-Walter has nothing to disclose.

5:30 PM 243 Intravenous Immunoglobulin as a treatment for intractable epilepsy secondary to focal cortical dysplasia Fatema Al Amrani, MD
Disclosure:
Dr. Al Amrani has nothing to disclose.

5:30 PM 244 Interpreting and Managing Subjective Cognitive Dysfunction in Adult Epilepsy Clinic Patients Lauren Gotterer, DO
Disclosure:
Dr. Gotterer has nothing to disclose.

5:30 PM 245 Patterns of Uses of Antiepileptic Drugs (AEDs) in A Tertiary Neurology Clinic in Khartoum City, Sudan Taha A-Hakam
Disclosure:
Dr. A-Hakam has nothing to disclose.

5:30 PM 246 Medical Education Improves Knowledge Involved in Clinical Decisions Following Inadequate Response to Antiepileptic Drug Therapy Stacey Hughes
Disclosure:
Dr. Hughes has nothing to disclose.

5:30 PM 247 Antiepileptic drug management in hospitalized epilepsy patients who cannot take their usual oral medications Anna Bank, MD
Disclosure:
Dr. Bank has nothing to disclose.

5:30 PM 248 The incidence of movement disorders after hemispherectomy in drug resistant epilepsy in children: one center’s experience. Sirorat Suwannachote, MD
Disclosure:
Dr. Suwannachote has nothing to disclose.

5:30 PM 249 Correlates of Epilepsy Prognosis in Qatar: An Epidemiological Perspective Fatima Al-Maadid
Disclosure:
Dr. Al-Maadid has nothing to disclose.

5:30 PM 250 NA NA NA
Disclosure:

Acute Cerebrovascular Interventional Therapies
Start Time Pub. Title Presenter
5:30 PM 251 Thrombectomy Outcomes in Acute Ischemic Stroke due to Middle Cerebral Artery M2 Occlusion with Stent-Retriever, Aspiration, and MERCI: Multi-Center Experience Kunakorn Atchaneeyasakul, MD
Disclosure:
Dr. Atchaneeyasakul has nothing to disclose.

5:30 PM 253 Is Endovascular Treatment Beneficial in Acute Ischemic Stroke Patients with M2 Segment Middle Cerebral Artery Occlusion? Emrah Aytac
Disclosure:
Dr. Aytac has nothing to disclose.

5:30 PM 254 Outcomes after Endovascular Therapy in a Population with Mild Acute Ischemic Stroke and Large Vessel Occlusion: Does Treatment Help? Christopher Fanale, MD
Disclosure:
Dr. Fanale has nothing to disclose.

5:30 PM 255 Outcomes after Endovascular Therapy in a Population with Mild Acute Ischemic Stroke: A 6.5 Year Observational Cohort Study at a High-Volume Comprehensive Stroke Center Christopher Fanale, MD
Disclosure:
Dr. Fanale has nothing to disclose.

5:30 PM 256 Outcomes for Endovascular Therapy for Large Vessel Occlusion in Patients 80 years and Older Nathaniel Wilson
Disclosure:
Dr. Wilson has nothing to disclose.

5:30 PM 257 Impact of Age on Revascularization and Early Outcomes Post Mechanical Thrombectomy in Acute Ischemic Strokes with Large Vessel Occlusion; A single center real world data analysis Muhammad Niazi, MD
Disclosure:
Dr. Niazi has nothing to disclose.

5:30 PM 258 Mechanical Thrombectomy in Large Vessel Occlusion Stroke Patients with Low CT ASPECT score Nirav Bhatt, MD
Disclosure:
Dr. Bhatt has nothing to disclose.

5:30 PM 259 Outcomes of Endovascular Thrombectomy with and without thrombolysis for acute large artery ischaemic stroke at a Tertiary Stroke Centre Chee Keong Wee, MD
Disclosure:
Dr. Wee has nothing to disclose.

5:30 PM 260 Effect size of acute thrombectomy stroke trials: comparison of completed vs terminated early Paisith Piriyawat, MD
Disclosure:
Dr. Piriyawat has nothing to disclose.

5:30 PM 261 Uncertainties of Endovascular Therapy Outside the AHA guidelines Amrou Sarraj, MD
Disclosure:
Dr. Sarraj has nothing to disclose.

5:30 PM 262 Primary Aspiration Thrombectomy in Acute Ischemic Stroke: A Single-Center Experience Ganesh Asaithambi, MD
Disclosure:
Dr. Asaithambi has nothing to disclose.

5:30 PM 263 Institution of Code Neurointervention Improves treatment times. Ashish Kulhari, MD
Disclosure:
Dr. Kulhari has nothing to disclose.

5:30 PM 264 Reducing Resource Utilization and Improving Efficiency Using A Separate Activation for Emergent Large Vessel Occlusion Ischemic Strokes Merrick Tan
Disclosure:
Dr. Tan has nothing to disclose.

5:30 PM 265 Does RAPID® reduce groin puncture times in Acute ischemic stroke? Haris Kamal, MD
Disclosure:
Dr. Kamal has nothing to disclose.

5:30 PM 266 Transfer Patients and Patients Presenting Directly to Endovascular Capable Centers Achieve Similar Good Outcome Rates with Endovascular Therapy Amrou Sarraj, MD
Disclosure:
Dr. Sarraj has nothing to disclose.

5:30 PM 267 Circadian timing of emergent large vessel occlusion and its association with efficacy of mechanical thrombectomy and patient outcomes. Bakhtier Nurmukhamedov, MD
Disclosure:
Dr. Nurmukhamedov has nothing to disclose.

5:30 PM 268 Factors correlating with reperfusion injury after endovascular therapy and tissue plasminogen activator for acute ischemic stroke Jazba Soomro, MD
Disclosure:
Dr. Soomro has nothing to disclose.

5:30 PM 269 Local Experience with a new retrievable stent (ERIC) in academic Center Dareen AlShaer, MD
Disclosure:
Dr. Alshaer has nothing to disclose.

5:30 PM 270 Statewide trends in utilization of endovascular treatment and outcomes: Analysis of Minnesota Hospital Association data (2014 and 2015) Haitham Hussein
Disclosure:
Dr. Hussein has nothing to disclose.

5:30 PM 271 Comparison of 6 mm diameter and 3-4 mm diameter stent retrievers for mechanical thrombectomy in acute ischemic stroke patients. Is Bigger Better? Ameer Hassan, DO
Disclosure:
Consultant for GE Healthcare, medtronic, penumbra, microvention and Stryker.

5:30 PM 272 Temporal Trends in the Rates of Endovascular Treatment for Patients Presenting with Acute Ischemic Stroke Natasha Hameed, MD
Disclosure:
Dr. Hameed has nothing to disclose.

5:30 PM 273 Role of Pial Collateral Flow in Acute Ischemic Stroke Outcomes Sumul Modi, MD
Disclosure:
Dr. Modi has nothing to disclose.

5:30 PM 274 Validation of Safer and Faster CT Imaging Technique to Assess Clot Size and Vessel Diameter in Acute Ischemic Stroke Interventions Ashish Kulhari, MD
Disclosure:
Dr. Kulhari has nothing to disclose.

5:30 PM 275 Should Wake Up and Unknown Time Onset Stroke Patients Be Lumped Together in Clinical Trials? Ketevan Berekashvili, MD
Disclosure:
Dr. Berekashvili has nothing to disclose.

SubAcute Interventional Therapies in Cerebrovascular Disease
Start Time Pub. Title Presenter
5:30 PM 277 Pattern of Utilization of Carotid Endarterectomy in Acute Ischemic Stroke Patients Undergoing Early Carotid Endarterectomy According to Severity of Neurological Deficits and Infarct Size Asad Ahrar
Disclosure:
Dr. Ahrar has nothing to disclose.

5:30 PM 278 Two-year Neurocognitive Outcomes in ≥70% Asymptomatic Carotid Stenosis by Intervention or Aggressive Medical Therapy: A Multimodal Approach Chun-Jen Lin
Disclosure:
Dr. Lin has nothing to disclose.

5:30 PM 279 Neurointerventional management in web vessels Ronie Piske
Disclosure:
Dr. Piske has nothing to disclose.

5:30 PM 280 Acute Extracranial-Intracranial Bypass in Acutely Symptomatic Atherosclerotic Occlusion Cory Rice, MD
Disclosure:
Dr. Rice has nothing to disclose.

5:30 PM 281 Implications of invasive vs non-invasive blood pressure measurements in neurointerventional procedures Sean Pauzauskie, MD
Disclosure:
Dr. Pauzauskie has nothing to disclose.

5:30 PM 282 MCA sphenoidal segment (M1): Incidence of bifurcation within horizontal segment and relevance in mechanical thrombectomy Mohtashim Qureshi
Disclosure:
Dr. Qureshi has nothing to disclose.

5:30 PM 283 Correlation of Carotid Arterial Bruit with Carotid Vascular Disease in Symptomatic Patients Guhan Ramamurthy, MBBS
Disclosure:
Dr. Ramamurthy has nothing to disclose.

5:30 PM 284 High Rate of Stenosis Progression Identified with Routine Carotid Doppler Surveillance Angelia Kirkpatrick
Disclosure:
Dr. Kirkpatrick has nothing to disclose.

5:30 PM 285 More to Atherosclerosis than Stenosis: Symptomatic Carotid Artery with Intraplaque Hemorrhage Samhitha Rai, MD
Disclosure:
Dr. Rai has nothing to disclose.

5:30 PM 286 A Systematic Literature Review of Patients with Carotid Web and Acute Ischemic Stroke. Parth Dhruv, MD
Disclosure:
Dr. Dhruv has nothing to disclose.

Stroke Recovery and Rehabilitation
Start Time Pub. Title Presenter
5:30 PM 287 Race/Ethnic Disparities for In-Hospital Mortality and Disability at Discharge after Acute Ischemic Stroke: Florida Puerto Rico Collaboration to Reduce Stroke Disparities Marialaura Simonetto
Disclosure:
Dr. Simonetto has nothing to disclose.

5:30 PM 288 Acute stroke, effect on mood, and music therapy: a non-pharmacological intervention Jessica Lee, MD, FAAN
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 289 Post Stroke Fatigue in African/Caribbean Americans: Role of Stroke Severity, Depression, and Quality of Life Alam Ahmed
Disclosure:
Dr. Ahmed has nothing to disclose.

5:30 PM 290 Gender Differences in Post Stroke Fatigue Clotilde Balucani, MD, PhD
Disclosure:
Dr. Balucani has nothing to disclose.

5:30 PM 291 Purpose in Life and Daytime Sleepiness in Post-Stroke Fatigue Alisen Huang
Disclosure:
Dr. Huang has nothing to disclose.

5:30 PM 292 Excessive Daytime Sleepiness and Depression in Stroke Survivors Quynh Pham, MD
Disclosure:
Dr. Pham has nothing to disclose.

5:30 PM 293 Dysphagia after stroke: State of the science and environmental survey of a comprehensive stroke center Nicole Langton-Frost
Disclosure:
Dr. Langton-Frost has nothing to disclose.

5:30 PM 294 Enteral tube feeding in acute ischemic stroke patients as a strong predictor of in-hospital stroke mortality MARIA SHEILA ROCHA, MD, PhD
Disclosure:
Dr. ROCHA has nothing to disclose.

5:30 PM 295 Feasibility of Integrating Post Stroke Rehabilitation and Recovery Assessments in Stroke Clinic Susan Taboada
Disclosure:
Dr. Taboada has nothing to disclose.

5:30 PM 296 Does Prior Use of Beta Blockers Affect Functional Outcomes Post Ischemic Stroke Endovascular Intervention? Rawan Albadareen, MD
Disclosure:
Dr. Albadareen has nothing to disclose.

5:30 PM 297 Predicting brain atrophy from resting-state functional connectivity and structural connectivity in ischemic stroke Ali Jannati
Disclosure:
Dr. Jannati has nothing to disclose.

5:30 PM 298 Association of Depression with Neuroimaging Markers of Brain Volumes and Vascular Disease: The Atherosclerosis Risk in Communities Study Elizabeth Fracica, MPH
Disclosure:
Dr. Fracica has nothing to disclose.

5:30 PM 299 Integrity of Normal Appearing White Matter and Functional Outcomes After Acute Ischemic Stroke Mark Etherton, MD
Disclosure:
Dr. Etherton has nothing to disclose.

5:30 PM 300 A motor rehabilitation BCI with multi-modal feedback in chronic stroke patients Christoph Guger
Disclosure:
Dr. Guger has received personal compensation for activities with g.tec Medical Engineering GmbH as an employee.

5:30 PM 301 The sequential and grammatically hierarchical recovery of receptive prosody after a right hemisphere stroke Justin Chandler, MD
Disclosure:
Dr. Chandler has nothing to disclose.

5:30 PM 302 Acute infarct volume accounts for a small fraction of explained variance in quality of life measures at 3 months Chen Lin, MD
Disclosure:
Dr. Lin has nothing to disclose.

Autonomic Neuropathies
Start Time Pub. Title Presenter
5:30 PM 303 Acute autonomic and sensory neuropathy: a case series Joel Gutierrez, MD
Disclosure:
Dr. Gutierrez has nothing to disclose.

5:30 PM 304 NMDA-receptor Autoimmunity and Opsoclonus-Myoclonus Syndrome Occurring with Rituximab Treatment of Autoimmune Autonomic Neuropathy Oana Dumitrascu, MD
Disclosure:
Dr. Dumitrascu has nothing to disclose.

5:30 PM 305 Familial dysautonomia: A disease with hidden tears Jose-Alberto Palma, MD, PhD
Disclosure:
Advisory member of Lundbeck. Managing editor of Clinical Autonomic Research.

5:30 PM 306 Non Amyloidogenic Mutation of Transthyretin Associated with Autonomic Neuropathy Todd Levine, MD
Disclosure:
Dr. Levine has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Griffons, Alexion, Nufactor, Diplomat, Shire, Corinthian Reference Labs. Dr. Levine holds stock and/or stock options in Corinthian Reference Labs. Dr. Levine has received research support from Alnylam, Malinckrodt.

5:30 PM 307 Spectrum of Autonomic Dysfunction in Sjögren Syndrome Brent Goodman, MD
Disclosure:
Dr. Goodman has nothing to disclose.

5:30 PM 308 A Case of Postganglionic Cholinergic Dysautonomia Improving with Bethanechol Bhumika Balgobin, MD
Disclosure:
Dr. Balgobin has nothing to disclose.

5:30 PM 309 Sympathetic skin response and heart rate variability as a surrogate of early small fiber involvement during routine peripheral neuropathy evaluation Rodolfo Callejas-Rojas, MD
Disclosure:
Dr. Callejas-Rojas has nothing to disclose.

5:30 PM 310 HIV-associated autonomic neuropathy: Relationship between vagal dysfunction and small intestinal bacterial overgrowth Elizabeth Pedowitz
Disclosure:
Dr. Pedowitz has nothing to disclose.

5:30 PM 311 Seropositive and seronegative presumed pediatric autoimmune dysautonomia: clinical features and immunotherapy Melissa Zhou
Disclosure:
Dr. Zhou has nothing to disclose.

Autonomic Manifestations of Neurologic and Systemic Disease
Start Time Pub. Title Presenter
5:30 PM 312 Idiopathic intracranial hypertension and autonomic neuropathy as the heralding manifestations of neuro-Behcet’s Glen Cook, MD
Disclosure:
Dr. Cook has nothing to disclose.

5:30 PM 313 Effects of Fingolimod on cardiovascular autonomic modulation after two years of therapy Max J. Hilz
Disclosure:
Dr. Hilz has received personal compensation for activities with Genzyme, A Sanofi. Dr. Hilz has received research support from the Rolf and Hubertine Schiffbauer Foundation, Bayer Health Care and Novartis Pharma GmbH,Germany.

5:30 PM 314 A Case of Lateral Medullary Infarction with Cardiovascular Autonomic Dysfunction: An Unusual Presentation Tridu Huynh
Disclosure:
Dr. Huynh has nothing to disclose.

5:30 PM 315 Autonomic dysfunction secondary to Whipple’s disease: a rare complication of a rare disorder Marie Grill, MD
Disclosure:
Dr. Grill has nothing to disclose.

5:30 PM 316 Postural orthostatic tachycardia predicts early conversion to multiple sclerosis after clinically isolated syndrome Magdalena Krbot Skoric
Disclosure:
Dr. Krbot Skoric has nothing to disclose.

5:30 PM 317 Symptoms of Autonomic Dysregulation after Traumatic Brain Injury Sophie Samuel
Disclosure:
Dr. Samuel has nothing to disclose.

Autonomic Disorders: Orthostatic Hypotension and Postural Tachycardia Syndrome
Start Time Pub. Title Presenter
5:30 PM 318 Predictors of response to droxidopa in patients with neurogenic orthostatic hypotension Jose-Alberto Palma, MD, PhD
Disclosure:
Advisory member of Lundbeck. Managing editor of Clinical Autonomic Research.

5:30 PM 319 Prospective Study of Real-World Outcomes in the Treatment of Neurogenic Orthostatic Hypotension With Droxidopa Steven Kymes
Disclosure:
Dr. Kymes has received personal compensation for activities with Lundbeck LLC and CVS Health as an employee. Dr. Kymes holds stock and/or stock options in CVS Health.

5:30 PM 320 Norepinephrine levels predicts the improvement in orthostatic symptoms after atomoxetine in patients with neurogenic orthostatic hypotension Cyndya Shibao
Disclosure:
Dr. Shibao has received personal compensation for activities with Lundbeck Pharmaceuticals and Thearavance Biopharma as a consultant.

5:30 PM 321 Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease L. Arthur Hewitt
Disclosure:
Dr. Hewitt has received personal compensation for activities with Lundbeck LLC as an employee.

5:30 PM 322 Sensory Neuropathic Symptoms in Postural Tachycardia Syndrome: Insights from a Cross-Sectional Community-Based Survey Lauren Stiles
Disclosure:
Dr. Stiles has nothing to disclose.

5:30 PM 323 Neurogenic Versus Non-neurogenic Orthostatic Hypotension - Practical Predictors for the Office Hyun Ah Kim
Disclosure:
Dr. Kim has nothing to disclose.

5:30 PM 324 Development of a new instrument to discriminate orthostatic from non-orthostatic symptoms: The Orthostatic Discriminant and Severity Scale Jacquie Baker
Disclosure:
Dr. Baker has nothing to disclose.

5:30 PM 325 Autonomic denervation of brain vessels in patients with NOH Juan Manuel Racosta
Disclosure:
Dr. Racosta has nothing to disclose.

5:30 PM 326 The effect of food intake on hemodynamic response to orthostasis in patients with postural orthostatic tachycardia syndrome Luka Crnošija, MD
Disclosure:
Dr. Crnosija has nothing to disclose.

Autonomic Testing
Start Time Pub. Title Presenter
5:30 PM 327 Altered Skin Preparation Eliminates Spuriously Absent Sudomotor Axon Reflex Responses Jeannie Corfits
Disclosure:
Dr. Corfits has nothing to disclose.

5:30 PM 328 Utility of Electroencephalography (EEG) during Tilt Table Evaluation for Syncope Srikanth Muppidi, MD
Disclosure:
Served on Scientifc Advisory board or meeting for Alexion and Lundbeck Pharmaceuticals .

Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes II
Start Time Pub. Title Presenter
329 WITHDRAWN NA NA
Disclosure:

5:30 PM 330 ASCEND Phase 3 Trial Open-Label Extension Study Results: Natalizumab May Delay Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) Hans-Peter Hartung, MD, FAAN
Disclosure:
Consulting and/or speaking fees (Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, and Sanofi Genzyme).

5:30 PM 331 Cerebrospinal Fluid (CSF) Cellular Analysis of Patients with Multiple Sclerosis (MS) Treated with Anti B-cell Therapy - Correlated with Treatment Response Allison Liang
Disclosure:
Dr. Liang has nothing to disclose.

5:30 PM 332 Alemtuzumab Improves Clinical Outcomes Over 4 Years in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up Alexey N Boyko, PhD,MD
Disclosure:
Dr. Boyko has received personal compensation for activities with Biogen Idec, Sanofi-Genzyme, Novartis, Teva, Merck-Serono, and Takeda as a consultant, advisor or speaker.

5:30 PM 333 Neuroprotective/neuroreparative activity of MIS416, a myeloid-directed innate immune therapeutic in Phase 2B trial for the treatment of secondary progressive multiple sclerosis Rebecca Girvan
Disclosure:
Dr. Girvan has received personal compensation for activities with Innate an Immunotherapeutics as an employee.

5:30 PM 334 MIS416, a myeloid targeted immune modulator for the treatment of secondary progressive multiple sclerosis acts directly within the CNS to induce Type I IFN and suppress neuroinflammation Reza Khorooshi
Disclosure:
Dr. Khorooshi has nothing to disclose.

5:30 PM 335 Myelin water imaging provides evidence of long-term remyelination and neuroprotection in Alemtuzumab treated multiple sclerosis patients Irene Vavasour, PhD
Disclosure:
Dr. Vasavour has nothing to disclose.

5:30 PM 336 Clinical and Radiologic Benefits of Alemtuzumab Over 5 Years in Patients of African Descent With Active RRMS Annette Okai
Disclosure:
Speaker / consultant: Biogen, Genetech, Mallinckrodt, Novartis, Sanofi Genzyme, Teva Neuroscience, TG Therapeutics. SunPharma, Sanofi Genzyme, Novartis, Alexion.

5:30 PM 337 Additional Efficacy Analyses from the Phase 2b SYNERGY Study Investigating the Anti-LINGO-1 Monoclonal Antibody Opicinumab for Treatment of Disabling Multiple Sclerosis Michelle Mellion, MD
Disclosure:
Dr. Mellion has received personal compensation for activities with Biogen has an employee. Dr. Mellion holds stock and/or stock options with Biogen.

5:30 PM 338 Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study Krzysztof W Selmaj
Disclosure:
Dr. Selmaj received personal compensation for activities with Biogen, Novartis, TEVA, Roche, Genzyme, Synthon, Receptos, and Bayer.

5:30 PM 339 Alemtuzumab Suppresses MRI Disease Activity Over 6 Years in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy: CARE-MS II Sven Schippling
Disclosure:
Dr. Schippling has received personal compensation for activities with Bayer Healthcare, Biogen, Sanofi Genzyme, Merck Serono, Novartis, and TEVA. Dr. Schippling has received research support from Sanofi Genzyme and Novartis.

5:30 PM 340 Fingolimod has diverse effects on gene expression by differentiating human neuronal progenitors Micheline McCarthy, MD,PhD, FAAN
Disclosure:
Dr. McCarthy has received research support from Novartis Pharmaceuticals.

5:30 PM 341 Persistent B lymphocytes in multiple sclerosis plaques after rituximab treatment Siamac esfandi
Disclosure:
Dr. esfandi has nothing to disclose.

5:30 PM 342 Improvements in Quality of Life Over 6 Years in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab: Results From the CARE-MS II Extension Study Rafael Arroyo González
Disclosure:
Dr. Arroyo Gonzalez has received personal compensation for activities with Novartis, Teva, Biogen, Sanofi Genzyme, Bayer, Celgene and Roche.

5:30 PM 343 MRI Outcomes in Patients Treated with Daclizumab in the EXTEND Open-Label Extension Study: Interim Report at Week 48 Stanley Cohan, MD, PhD
Disclosure:
Dr. Cohan has received personal compensation for activities with Biogen, Mallinckrodt, Novartis and Sanofi-Genzyme, Acorda, Genentech. Dr. Cohan has received research support from Biogen, Genentech, Mallinckrodt, Novartis, Opexa, Roche and Sanofi-Genzyme.

5:30 PM 345 Using Diffusion Tensor Imaging to Quantify Effects of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis Patients Jenny Feng
Disclosure:
Dr. Feng has nothing to disclose.

5:30 PM 346 Tecfidera modulates short term metabolomic signatures in people with multiple sclerosis Constantinos Savva
Disclosure:
Dr. Savva has nothing to disclose.

5:30 PM 347 Efficacy and safety of alemtuzumab in 113 patients with active relapsing-remitting MS: one-year follow-up in France xavier ayrignac
Disclosure:
Dr. ayrignac has nothing to disclose.

5:30 PM 348 Relationship between MRI Lesion Count and B Cell Count Reduction under Ofatumumab Treatment Marina Savelieva
Disclosure:
I am an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland. Author is an employee of Novartis Pharma AG, Switzerland.

5:30 PM 349 Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 Barry Singer, MD
Disclosure:
Dr. Singer has received personal compensation for activities with Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and Teva CNS as a speaker and/or consultant. Dr. Singer has received research support from Acorda, Biogen, MedImmune, Novartis, Roche, and Sanofi Genzyme.

5:30 PM 350 Impact of fingolimod on MRI brain volume measures in routine clinical practice: results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients Robert Zivadinov, MD, PhD, FAAN
Disclosure:
Dr. Zivadinov has received personal compensation for activities with EMD Serono, Genzyme, Novartis, for speaking and consultant fees. Dr. Zivadinov has received personal compensation in an editorial capacity for BioMed Research International, BMC Medicine, BMC Neurology, Clinical CNS Drugs, Conf Pap Neurosci, Journal of Alzheimer's Disease, Vein and Lymphatics, and Word J Surg Proc. Dr. Zivadinov has received research support from Biogen Idec, Claret Medical, Genzyme, Intekrin-Coherus, Novartis, and Teva Pharmaceuticals.

5:30 PM 351 Effect of the natalizumab treatment on cererospinal fluid measures in multiple sclerosis: a longitudinal study. Barbora Benova
Disclosure:
Dr. Benova has received personal compensation for travel and conference fees from Novartis and Sanofi Genzyme.

5:30 PM 352 Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis over 24 months Jesper Hagemeier
Disclosure:
Dr. Hagemeier has nothing to disclose.

5:30 PM 353 Predictive biomarkers for optimal therapeutic response to fingolimod treatment in MS patients Bibiana Quirant-Sanchez
Disclosure:
Dr. Quirant-Sanchez has nothing to disclose.

5:30 PM 354 A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis Sheena Dupuy
Disclosure:
Dr. Dupuy has nothing to disclose.

5:30 PM 355 Comparing 5 year clinical-MRI relationships in two comprehensive care multiple sclerosis centers in the SUMMIT study Rohit Bakshi, MD, FAAN
Disclosure:
Dr. Bakshi has received personal compensation for activities with AbbVie, EMD-Serono, Genentech Inc., and Novartis as a consultant. Dr. Bakshi has received research support from Biogen, EMD-Serono, Novartis, and Sanofi/Genzyme.

5:30 PM 356 Effects of Alemtuzumab on Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS) Regina Berkovich, MD, PhD
Disclosure:
D.r Berkovich has received personal compensation for activities with Acorda, Avanir, Bayer, Biogen, Sanofi Genzyme, Novartis, Questcor, and Teva Neuroscience as an Advisory Board Member and a consultant.

5:30 PM 357 Progression of Whole Brain and Gray Matter Atrophy in Relapsing MS Despite Treatment with Natalizumab Adil Javed, MD, PhD
Disclosure:
Dr. Javed has received personal compensation for activities with Teva Neuroscience, Bayer Pharmaceuticals Corp., Novartis, and Biogen Idec as a consultant and speaker.

5:30 PM 358 A potential role for continuation of natalizumab therapy in patients with secondary progressive multiple sclerosis. Siew Mei Yap
Disclosure:
Dr. Yap has nothing to disclose.

5:30 PM 359 Sustained Disability Improvement as Assessed by a Multicomponent Endpoint in Secondary Progressive Multiple Sclerosis (SPMS) Patients: A Post Hoc Analysis from ASCEND Gavin Giovannoni, MD
Disclosure:
Dr. Giovannoni has received personal compensation for activities with AbbVie, Bayer HealthCare, Biogen, Canbex, FivePrime, Genzyme, GlaxoSmithKline, GW Pharma, Merck Serono, Novartis, Protein Discovery Laboratories, Roche, Synthon, Teva Neuroscience, UCB, and Vertex for honoraria. Dr. Giovannoni has received personal compensation from Elsevier in a co-chief editor capacity of MS and Related Disorders. Dr. Giovannoni has received research support from Biogen, Ironwood, Merck Serono, Merz, and Novartis.

5:30 PM 360 Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up Celia Oreja-Guevara, MD
Disclosure:
Dr. Oreja Guevara has received personal compensation for activities with Biogen Idec, Novartis, Sanofi Genzyme, Roche Diagnostics Corporation, Merck, and Teva Neuroscience.

5:30 PM 361 Real World Effectiveness of First-Line Use of Gilenya: A Two-Site Retrospective Study Sarah M Planchon
Disclosure:
Dr. Planchon has nothing to disclose.

5:30 PM 362 Evaluation of neurological improvements in secondary progressive multiple sclerosis patients treated with myeloid targeted immune modulator MIS416 Gill Webster, PhD
Disclosure:
Dr. Webster has nothing to disclose.

5:30 PM 363 Safety and Efficacy of Delayed-release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from Asia-Pacific and Other Countries: Interim Analysis of the APEX Extension Study Takahiko Saida
Disclosure:
Dr. Saida has received personal compensation for activities Ono Pharmaceutical, Biogen Japan, TDS Japan, and Takeda Pharmaceutical; AstellasPharma, Byer, Daiichi Sankyo, Kaketsuken, Merck Serono, Mitsubishi Tanabe Pharma, Nihon Pharmaceutical, and Novartis Pharmaceuticals as an advisory board member.

5:30 PM 364 Cellular composition of peripheral blood mononuclear cells during 4 years long-term treatment with fingolimod Thomas Dehmel
Disclosure:
Dr. Dehmel has received personal compensation for activities with Biogen.

5:30 PM 365 5 years safety of fingolimod in real world: First results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice Tjalf Ziemssen, MD
Disclosure:
Dr. Ziemssen has received personal compensation for activities with Bayer HealthCare, Biogen, Elan, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Synthon and Teva as a speaker, committee and advisory board member.

5:30 PM 366 Alemtuzumab; The Walton Centre Experience Mona Ghadiri-Sani, MD, MBBS, BSc
Disclosure:
Dr. Ghadiri-Sani has nothing to disclose.

5:30 PM 367 Alemtuzumab Improves Patient-Reported Quality of Life Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients With Highly Active Disease: Results From the CARE-MS II Extension Study Rafael Arroyo González
Disclosure:
Dr. Arroyo Gonzalez has received personal compensation for activities with Novartis, Teva, Biogen, Sanofi Genzyme, Bayer, Celgene and Roche.

Disease Modifying Therapy for Multiple Sclerosis: Risk Assessment and Safety
Start Time Pub. Title Presenter
5:30 PM 368 Reduction in JCV antibody titers in multiple sclerosis patients treated with rituximab Ursela Siddiqui
Disclosure:
Dr. Siddiqui has nothing to disclose.

5:30 PM 369 Safety and Tolerability of Opicinumab in Relapsing Multiple Sclerosis: the Phase 2b SYNERGY Trial Peter McCroskery
Disclosure:
Dr. McCroskery has received personal compensation for activities with Biogen as an employee. Dr. McCroskery holds stock and/or stock options in Biogen.

5:30 PM 370 Natalizumab therapy is associated with greater variability in JC Virus Antibody levels John Peters
Disclosure:
Dr. Peters has nothing to disclose.

5:30 PM 371 Retrospective review on the prevalence of lymphopenia in patients aged 55 years and over taking oral disease-modifying therapies for multiple sclerosis Clover Youn
Disclosure:
Dr. Youn has nothing to disclose.

5:30 PM 372 Dimethyl fumarate can cause a severe reduction in CD8+ cells without causing significant total lymphopenia Casey Spinelli
Disclosure:
Dr. Spinelli has nothing to disclose.

5:30 PM 373 Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis: Effects of Dose Reduction on Lymphopenia Ka-Ho Wong
Disclosure:
Dr. Wong has nothing to disclose.

5:30 PM 374 Exploratory PML risk assessment on Extended Interval Natalizumab Dosing. Lana Zhovtis Ryerson, MD
Disclosure:
Dr. Zhovtis Ryerson has received personal compensation for activities with Biogen Idec and Teva as a speaker and advisory board member. Dr. Zhovtis Ryerson has received research support from Biogen Idec.

5:30 PM 375 Safety, Tolerability, and Pharmacodynamics of Intravenous and Subcutaneous Doses of the Anti-CD52 Antibody GLD52 in Patients With Progressive MS: A Randomized, Controlled, Single Ascending Dose Trial David H Margolin*, MD,PhD
Disclosure:
Dr. Margolin has received personal compensation for activities with Sanofi Genzyme as an employee.

5:30 PM 376 Characterization of Baseline Lymphocytes and Their Influence on Subsequent ALC and Lymphocyte Subset Decline in Patients with Relapsing Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate in a Retrospective, Multicenter, Observational Study (REALIZE) Guy Buckle, MD
Disclosure:
Dr. Buckle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD-Serono, Genentech, Genzyme, Novartis, Mallinckrodt, and Teva pharmaceuticals.

5:30 PM 377 Predictive Factors of Intolerability to Dimethyl Fumarate Adnan Subei, DO
Disclosure:
Dr. Subei has nothing to disclose.

5:30 PM 378 Phase I Clinical Trial Demonstrates Safety and Efficacy of Intrathecal Autologous Mesenchymal Stem Cell-Derived Neural Progenitors (MSC-NPs) for the Treatment of Progressive Multiple Sclerosis Violaine Harris, PhD
Disclosure:
Dr. Harris has nothing to disclose.

5:30 PM 379 Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension Per Soelberg-Sorensen
Disclosure:
Dr. Soelberg-Sorensen has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan, and GlaxoSmithKline, and Bayer. Dr. Soelberg-Sorensen has received personal compensation in an editorial capacity for European Journal of Neurology, Multiple Sclerosis Journal, European Journal of Neurology, and Therapeutic Advances in Neurological Disorders. Dr. Soelberg-Sorensen has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, the Danish Multiple Sclerosis Society, and the Danish Medical Research Council.

5:30 PM 380 Interim Results of an Open-Label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients with Relapsing-remitting Multiple Sclerosis Christian Von Hehn
Disclosure:
Dr. Von Hehn has received personal compensation for activities with Biogen as an employee. Dr. Von Hehn holds stock and/or stock options in Biogen

5:30 PM 381 Prospective and Open label study to compare the cardiac safety profile during first-dose monitoring period of two Fingolimod products: (Gilenya vs Generic version) in RRMS patients María Celeste Curbelo
Disclosure:
Dr. Curbelo has received personal compensation for activities with Biogen, IVAX, Genzyme, Merck and Synthon-Bago.

5:30 PM 382 Title Effect of DMT’s on lymphocytes and infections Salvatore Napoli, MD
Disclosure:
Dr. Napoli has received personal compensation for activities with Teva, Sanofi, EMD Serono, Biogen, Novartis, Acorda, and Mallinkrodt.

5:30 PM 383 Safety of Delayed-release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis Patients from ENDORSE: Seven-Year Interim Results Carlo Pozzilli
Disclosure:
Dr. Pozzilli has received personal compensation for activities with Almirall, Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva as a speaker and consultant. Dr. Pozzilli has received research support from Almirall, Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva.

5:30 PM 384 Clinical and Safety Outcomes From Patients Treated With Teriflunomide in the Phase 4 Teri-PRO Study Ralf Gold, MD
Disclosure:
Dr. Gold has received personal compensation for activities with Bayer HealthCare, Biogen, Merck Serono, Novartis, and Teva Neuroscience as a speaker. Dr. Gold has received personal compensation in an editorial capacity for Sage. Dr. Gold has received research support from Bayer HealthCare, Biogen, Merck Serono, Novartis, and Teva Neuroscience.

5:30 PM 385 Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis David Bargiela, MBBS
Disclosure:
Dr. Bargiela has nothing to disclose.

5:30 PM 386 A Risk Aversion Calculator for Multiple Sclerosis Immunomodulator Selection: a Patient-Centered Approach Fletcher Hartsell, MD, MPH
Disclosure:
Dr. Hartsell has received personal compensation for activities with EMD Serono and Genzyme as a consultant.

5:30 PM 387 EEG findings and clinico-radiographic correlation in nataluzimab-associated progressive multifocal leukoencephalopathy Zehra Husain, MD
Disclosure:
Dr. Husain has nothing to disclose.

5:30 PM 388 Shared decision making in Multiple Sclerosis: Revisiting the psychometric properties of the SDM-Q-9 questionnaire Javier Ballesteros
Disclosure:
Dr. Ballesteros has nothing to disclose.

5:30 PM 389 Possible cerebral toxoplasmosis in a fingolimod- treated MS patient Marinella Clerico, MD
Disclosure:
Dr. Clerico has received personal compensation for activities with EMD Serono and Biogen as an advisory board member.

5:30 PM 390 HSV Encephalitis associated with off-label Rituximab use in a case of relapsing multiple sclerosis. Aparna Vaddiparti, MD
Disclosure:
Dr. Vaddiparti has nothing to disclose.

5:30 PM 391 Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management Robert Fox, MD, FAAN
Disclosure:
Consultant fees from Actelion, Biogen, Genentech, Mallinckrodt, MedDay, Novartis, and Teva... Research support from Biogen (clinical trial contracts) and Novartis (research study support).

5:30 PM 392 Dimethyl fumarate-induced lymphopenia: effects on T-cell activation and function Erin Longbrake, MD, PhD
Disclosure:
Dr. Longbrake has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, EMD Serono, Teva and Sanofi Genzyme.

5:30 PM 393 Glatiramer Acetate Induced Serum Sickness Paul Ferguson
Disclosure:
Dr. Ferguson has received personal compensation for activities with Biogen Idec and Sanofi-Genzyme as a speakers bureau member. Dr. Ferguson has received research support from Novartis and Sun Pharmaceuticals.

5:30 PM 394 Cladribine tablets in the treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program Stuart Cook, MD, FAAN
Disclosure:
Dr. Cook has received personal compensation for activities with Merck Serono, Bayer HealthCare, Sanofi-Aventis, Neurology Reviews, Biogen Idec, Teva Pharmaceuticals, and Actinobac Biomed Inc., as a lecturer, consultant, or advisory board member.

5:30 PM 395 An examination of lymphocyte subpopulations in MS patients on dimethyl fumarate before and after therapy coupled with analysis of JCV testing Christopher Perrone, MD
Disclosure:
Dr. Perrone has nothing to disclose.

5:30 PM 396 Tolerability and safety of Fingolimod in Spanish Clinical practice. Pooled Analysis data: Study Fingoview Guillermo Izquierdo, MD
Disclosure:
Speaking and advisory from Bioge Idec, Merck Serono, Sanofi, Teva, Novartis, Genzyme, Almirall and Roche. I received speaking honoraria from Biogen, Novartis, Sanofi, Merck Serono and Teva.

5:30 PM 397 Effect of Extended Interval Dose Natalizumab therapy on CD19+ and CD34+ cell mobilization from bone marrow and JC Viremia. Lana Zhovtis Ryerson, MD
Disclosure:
Dr. Zhovtis Ryerson has received personal compensation for activities with Biogen Idec and Teva as a speaker and advisory board member. Dr. Zhovtis Ryerson has received research support from Biogen Idec.

5:30 PM 398 A four year immunological study of responsive and non responsive MS patients after alemtuzumab to search for indications of retreatment Luca Durelli, MD
Disclosure:
Dr. Durelli has received personal compensation for activities with Sanofi Genzyme.

5:30 PM 399 Development of an Automated Blood Monitoring Algorithm for Alemtuzumab-Treated Patients Krista Barclay
Disclosure:
Dr. Barclay has received personal compensation for activities with Genzyme as a consultant.

5:30 PM 400 Symptomatic Thrombocytopenia After One Dose of Alemtuzumab With Successful Rechallenge Andrea Derlet
Disclosure:
Dr. Derlet has nothing to disclose.

5:30 PM 401 Safety monitoring of alemtuzumab therapy in active relapsing multiple sclerosis: necessary, manageable but resource-intensive. Siew Mei Yap, MBBS
Disclosure:
Dr. Yap has nothing to disclose.

5:30 PM 402 Infectious diseases safety protocol in multiple sclerosis patients treated with alemtuzumab. Real-world implementation and outcomes. Jose Meca Lallana
Disclosure:
J. Meca-Lallana has received consulting or speaking fees from Almirall, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva..

5:30 PM 403 Case report: Leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment Lore Garten, MD
Disclosure:
Dr. Garten has nothing to disclose.

5:30 PM 404 Prediction of long-term persistency of Natalizumab anti-drug antibodies Florian Deisenhammer, MD
Disclosure:
Speaking and andvising for Biogen, Genzyme, Merck, Novartis, Roche, TEVA; has received unrestricted research grant by Biogen..

5:30 PM 405 Different infusion reaktions of two treatment schedules with alemtuzumab in patients with multiple sclerosis Peter Von Wussow
Disclosure:
Dr. Von Wussow has received personal compensation for activities with Genzyme and Biotest for participating on advisory boards.

5:30 PM 406 Pneumonitis as an early complication of alemtuzumab treatment Daniel Kantor, MD, FAAN
Disclosure:
Abbvie, Avanir, Bayer, Biogen, EMD Serono, Genzyme, Mylan, Novartis, Sandoz -- consulting services and speaking honoraria..

5:30 PM 407 Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis Ludwig Kappos, MD
Disclosure:
All payments have been transferred to a research account of the University Hospital Basel -> NO Personal compensation. To institution (University Hospital Basel) license fees for Neurostatus products and grants from Bayer, Biogen, Merck, Novartis, Roche, Teva, Roche Research Foundation, Swiss MS Society, and Swiss National Research Foundation.

5:30 PM 408 The safety and efficacy of Rituximab Use in Secondary-Progressive Multiple Sclerosis (SPMS) at UMMHC: five years follow up data Idanis Berrios Morales, MD
Disclosure:
Dr. Berrios Morales has nothing to disclose.

Emerging Science
Start Time Pub. Title Presenter
8:30 AM 409 3D Mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells promote resistance to current standard-of-care therapy Daniela Bota, MD
Disclosure:
Dr. Bota has received personal compensation from Novocure and ERC Belgium for speaking.

Emerging Science
Start Time Pub. Title Presenter
8:30 AM 410 Cholinesterase Inhibitor Use and Cognitive Decline in Mild Cognitive Impairment and Mild Dementia due to Alzheimer Disease Jee-young Han
Disclosure:
Dr. Han has nothing to disclose.

Emerging Science
Start Time Pub. Title Presenter
8:30 AM 411 Seizures are locked to long time-scale rhythms in epilepsy Maxime Baud, MD, PhD
Disclosure:
Dr. Baud has nothing to disclose.

Emerging Science
Start Time Pub. Title Presenter
8:30 AM 412 The differential effects of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on seizure frequency in patients with drug-resistant epilepsy – A Randomized, double-blind, placebo-controlled trial Ahmed Daak, MD, PhD
Disclosure:
I am currently working as the Vice President of Medical Research of Sancilio Pharmaceutical Companay .

Register Now

Related Courses

Saturday April 21, 2018

7:00 AM-9:00 AM
C1 Mild Cognitive Impairment: Implications for Clinicians Ronald Petersen PhD, MD, FAAN
C3 Emergency Room Neuro-ophthalmology Heather Moss MD, PhD, FAAN
C4 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
9:30 AM-11:30 AM
C8 Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Jose Suarez MD
C9 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Amanda Peltier MD, MS
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN
C13 Neuroimaging Biomarkers Across the Dementia Spectrum Liana Apostolova MD, FAAN
C14 Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
C10 More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease Farrah Daly MD, MBA
12:00 PM-4:00 PM
C16 Neurophysiologic Intraoperative Monitoring Skills Workshop (Registration Required) Aatif Husain MD
1:30 PM-3:30 PM
C18 Pediatric Neuro-ophthalmology Update Christopher Glisson DO
C20 Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Amanda Peltier MD, MS
C21 Stroke in Young Adults and Women Aneesh Singhal MD, FAAN
C19 The Neurology of Social Behavior Bradford Dickerson MD
C23 Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN
C22 Critical Care Consultations for Neurohospitalists Vanja Douglas MD

Sunday April 22, 2018

7:00 AM-9:00 AM
C24 Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
C25 Neuro-ophthalmology I: Visual Loss, Optic Neuropathies, and Papilledema Nancy Newman MD, FAAN
C26 Neurological Intensive Care I: The Essentials David Greer MD, FAAN
C30 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies Michael Shy MD
C31 Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates Ellen Bubrick MD
C32 Clinicopathological Correlation Session in Dementia David Irwin MD
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
C29 Controversies in Stroke Treatment and Prevention Steven Messe MD, FAAN, FAHA
9:15 AM-12:00 PM
PL2 Presidential Plenary Session
1:00 PM-3:00 PM
C36 Nonmotor Manifestations of Parkinson's Disease I Charles Adler MD, PhD, FAAN
C37 Neurological Intensive Care II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction Kristine O'Phelan MD
C40 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies Michael Shy MD
C41 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases Joseph Sirven MD, FAAN
C43 Neuro-ophthalmology II: Optic Neuritis, Visual Fields, and Anisocoria Nancy Newman MD, FAAN
1:00 PM-5:30 PM
C47 Neuromuscular Ultrasound Skills Workshop (Registration Required) Craig Zaidman MD
3:30 PM-5:30 PM
C50 Nonmotor Manifestations of Parkinson's Disease II Charles Adler MD, PhD, FAAN
C51 Neurological Intensive Care III: Vascular Diseases Lori Shutter MD, PT
C54 Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing Michael Shy MD
C56 Neuro-ophthalmology III: Diplopia, Ocular Motility Disorders, and Nystagmus Nancy Newman MD, FAAN
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Monday April 23, 2018

7:00 AM-9:00 AM
C60 Neuro-ophthalmology: Overview and Update Nancy Newman MD, FAAN
C61 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Michael Weiss MD, FAAN
C64 Update on Medical Management of Stroke Natalia Rost MD, MPH, FAAN
C66 Cognitive Impairment due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment David Knopman MD, FAAN
C65 Video EEG: Name That Spell Amy Crepeau MD
C58 Balance and Gait Disorders Bastiaan Bloem MD, PhD
1:00 PM-3:00 PM
C75 Therapeutic Temperature Modulation in the ICU Stephan Mayer MD
C67 Evaluating Tremor in the Office Vicki Shanker MD
C69 Sports Neurology: Enhancing Athletic Performance Kevin Crutchfield MD
C71 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Jeffrey Gelfand MD, MAS, FAAN
C73 Clinical Approach to Muscle Disease I: Muscle Disorders and Rhabdomyolysis Tahseen Mozaffar MD, FAAN
C77 Present and Future Biomarkers in Dementia: A Case-based Approach Jonathan Graff-Radford MD
C74 Epilepsy Surgery Update Stephan Schuele MD, FAAN
1:00 PM-5:30 PM
C82 Neuro-ophthalmology and Neurovestibular Exam Lab Skills Workshop John Pula MD, FAAN
3:30 PM-5:30 PM
N2 Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy John Day MD, PhD,
Richard Finkel MD
C86 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II Jeffrey Gelfand MD, MAS, FAAN
C88 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Tahseen Mozaffar MD, FAAN
C91 Chronic Traumatic Encephalopathy: Update Andrew Budson MD
C94 Spanish: Update CNS Infections and Tropical Medicine Oscar Del Brutto MD, FAAN

Tuesday April 24, 2018

7:00 AM-9:00 AM
C95 Status Epilepticus Stephan Schuele MD, FAAN
C96 Vascular Cognitive Impairment and Dementia: Current Status and Future Larry Goldstein MD, FAAN, FAHA
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
C99 Basic Principles of Brain Tumors: For Practice and for Certification Erin Dunbar MD
C101 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease Irene Litvan MD, FAAN
C102 Now You See It, Now You Know It: Pathognomonic Neuro-ophthalmology Examination Findings Wayne Cornblath MD, FAAN
C103 Sports Concussion Skills Workshop: Event Coverage Skills Vernon Williams MD
1:00 PM-3:00 PM
N3 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology Guy Rouleau MD, PhD,
Massimo Pandolfo MD, FAAN
C104 Critical Care EEG Monitoring Suzette LaRoche MD, FAAN
C105 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Daniel Kaufer MD, FAAN
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
C108 Neurologic Complications in Adults with Down Syndrome Andrea Gropman MD
C112 Concussion: From Mechanisms to Management David Dodick MD, FAAN
C113 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia John Morgan MD, PhD
C114 Cerebrovascular Disease I: Prevention Larry Goldstein MD, FAAN, FAHA
1:00 PM-5:30 PM
C118 EMG Skills Workshop: Basic Ezgi Tiryaki MD, FAAN
3:30 PM-5:30 PM
C119 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome Ligia Onofrei MD
C129 Disorders of Motor Programming: The Apraxias and Action-Intentional Disorders Chalk Talk Kenneth Heilman MD, FAAN
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD
C122 Child Neurology: A Case-based Approach Elaine Wirrell MD, FAAN
C123 The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders Tobias Walbert MD, PhD
C126 Concussion: Evaluation and Management in the Acute and Chronic Phases David Dodick MD, FAAN
C127 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics John Morgan MD, PhD
C128 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Philip Gorelick MD, MPH, FAAN

Wednesday April 25, 2018

7:00 AM-9:00 AM
C139 Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
C137 Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Selim Benbadis MD
C134 Neurocognitive Assessment for Neurologists Mario Mendez MD, PhD, FAAN
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
C141 Mastering EMG Waveform Recognition Skills in Just Two Hours! Devon Rubin MD, FAAN
C132 Higher Cortical Visual Disorders: Case-based Review Sashank Prasad MD
C142 Evaluation and Treatment of Common Spine Disorders J. D. Bartleson MD, FAAN
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C155 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults Katherine Noe MD, PhD, FAAN
C144 Severe TBI: From ICU to Rehabilitation Susanne Muehlschlegel MD,MPH
C145 Non-Alzheimer's Dementia I: Frontotemporal Dementias Gil Rabinovici MD
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
C148 Neurologic Consultations in Cancer Patients I Amy Pruitt MD
C150 Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Philip Gorelick MD, MPH, FAAN
C151 Nystagmus and Saccadic Intrusions Made Simple Janet Rucker MD
C154 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Christopher Gibbons MD, FAAN
1:00 PM-5:30 PM
C158 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop Diego Torres-Russotto MD, FAAN
3:30 PM-5:30 PM
C169 Clinical EEG III: Neonatal and Pediatric Nicholas Abend MD
C160 Non-Alzheimer's Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias Gil Rabinovici MD
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD
C163 Neurologic Consultations in Cancer Patients II Patrick Wen MD, FAAN
C165 Cerebrovascular Disease IV: Telestroke Eric Anderson MD, PhD
C166 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia Janet Rucker MD
C168 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System Christopher Gibbons MD, FAAN
C170 Spanish: Update on Epilepsy Therapy Andres Kanner MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C178 Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
C171 Clinical Epilepsy I: Basics Tracey Milligan MD, FAAN
C173 Rehabilitation in Neurology Marc Slutzky MD, PhD
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
C177 Neuro-oncology in 2018: Navigating Current Trends Maciej Mrugala MD
C180 Preventive Neurology: How Neurologists Can Improve Outcomes That Matter to Patients Joel Salinas MD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN
C192 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Neurodegenerative Rapidly Progressive Dementia Michael Geschwind MD, PhD
C191 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Mark Bromberg MD, PhD, FAAN
C181 Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly Barbara Jobst MD, FAAN
C183 Behavioral Neurology I: Network Anatomy of Behavior and Language Maria Gorno Tempini MD, PhD
C185 Myelopathies I: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes Benjamin Greenberg MD, FAAN
C186 Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
C189 Neuro-oncologic Predicaments in the Hospital Setting Na Tosha Gatson MD, PhD
C190 Neuro-otology I: The Common Peripheral Vestibular Disorders Kevin Kerber MD
C194 Spanish: Update on Stroke Therapy Carlos Kase MD, FAAN, FAHA
1:00 PM-5:30 PM
C195 Brain Death Skills Workshop: How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family Panayiotis Varelas MD, PhD
3:30 PM-5:30 PM
N6 Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation Antonio Omuro MD,
Andreas Hottinger MD
C207 Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia Michael Geschwind MD, PhD
C205 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
C196 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Tobias Loddenkemper MD
C197 Behavioral Neurology II: Memory and Attention Maria Gorno Tempini MD, PhD
C199 Myelopathies II: Approaches to Rehabilitation and Psychosocial Challenges Benjamin Greenberg MD, FAAN
C202 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease Dileep Yavagal MD, FAAN
C204 Neuro-otology II: Diagnosis and Treatment of Nuanced Causes of Dizziness Kevin Kerber MD
C208 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop Allison Brashear MD, MBA, FAAN
6:30 PM-9:30 PM
C209 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease Anne Connolly MD, FAAN
C210 Case Studies in the ICU Nicholas Silvestri MD, FAAN
C212 Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN
C214 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration Daniel Kaufer MD, FAAN

MEMBER LOG IN

Forgot Password?